Intellectual Property Rights and International Trade

Shayerah Ilias Akhtar
Specialist in International Trade and Finance

Ian F. Fergusson
Specialist in International Trade and Finance

April 4, 2014
Summary

This report provides background on intellectual property rights (IPR) and discusses the role of U.S. international trade policy in enhancing IPR protection and enforcement abroad. IPR are legal rights granted by governments to encourage innovation and creative output by ensuring that creators reap the benefits of their inventions or works. They may take forms such as patents, trade secrets, copyrights, trademarks, or geographical indications. Congress has constitutional responsibility for legislating and overseeing IPR and international trade policy. Responsibility for developing IPR policy, engaging in IPR-related international negotiations, and enforcing IPR laws cuts across multiple U.S. government agencies.

The protection and enforcement of IPR is an important and longstanding component of U.S. international trade policy and U.S. trade negotiating objectives. U.S. trade policy also seeks to address new and evolving issues in the IPR landscape related to the growing role of emerging markets in the global market place and the increased level of digital trade.

Since the North American Free Trade Agreement (NAFTA) and the 1995 Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement) at the World Trade Organization (WTO), trade policy has been used to advance IPR rules internationally. The TRIPS Agreement set minimum standards for IPR protection and enforcement. The United States engages in efforts with other trading partners to build on the TRIPS Agreement, particularly through the negotiation of regional and bilateral free trade agreements (FTAs). To date, the United States has entered into 14 FTAs with 20 countries, which generally include IPR commitments exceeding obligations under the TRIPS Agreement. The May 10, 2007, bipartisan trade agreement modified some of the IPR requirements in the U.S. FTAs with Peru, Panama and Colombia, allowing for greater flexibility for these developing countries to meet both their IPR obligations and public health needs. IPR issues are prominent in the ongoing U.S. FTA negotiations of the proposed Trans-Pacific Partnership (TPP) and Transatlantic Trade and Investment Partnership (TTIP). The United States also seeks to build on the TRIPS Agreement in other ways, such as through the negotiation of the Anti-Counterfeiting Trade Agreement (ACTA).

Other trade policy tools also are available to advance U.S. international IPR objectives. Pursuant to Section 182 of the Trade Act of 1974 as amended (P.L. 93-618), the Office of the U.S. Trade Representative (USTR) identifies countries providing inadequate IPR protection in its annual “Special 301” report. Section 337 of the amended Tariff Act of 1930 authorizes the U.S. International Trade Commission (ITC) to prohibit U.S. imports that infringe on U.S. IPR. Additionally, under the Generalized System of Preferences (GSP), the United States may consider a developing country’s IPR policies and practices as a basis for offering or suspending preferential duty-free entry to certain products from the country.

IPR issues related to international trade policy may figure prominently in the 113th congressional agenda. Congress may:

- examine the role of IPR in U.S. trade policy, including through consideration of IPR trade negotiating objectives in a renewal of Trade Promotion Authority (TPA);
- conduct oversight of implementation of the IPR commitments in existing trade agreements, as well as in the current U.S. trade negotiations on the TPP and TTIP;
• conduct oversight of the role of IPR in U.S. economic growth and innovation, and how the protection and enforcement of IPR relates to other public policy goals, such as access to medicines in poor or developing countries and the free flow of data;

• consider the possibility of additional policy options to address IPR concerns in emerging economies that are not a part of existing U.S. FTAs or included in current U.S. FTA negotiations, as well as new and evolving IPR issues, such as with respect to indigenous innovation, “forced” localization barriers to trade, and trade secret theft through cybercrime; and

• examine the effectiveness of the current U.S. coordinating structure and the adequacy of current federal resources for promoting international IPR support.
# Contents

Introduction ...................................................................................................................................... 1  
Intellectual Property Rights Basics .................................................................................................. 1  
   Types of IPR ................................................................................................................................ 1  
      Patents ................................................................................................................................... 2  
      Trade Secrets .......................................................................................................................... 2  
      Copyright ............................................................................................................................... 2  
      Trademarks ............................................................................................................................ 3  
   Infringement of IPR ..................................................................................................................... 3  
      Piracy ................................................................................................................................... 4  
      Counterfeiting ....................................................................................................................... 4  
Innovation Indicators ....................................................................................................................... 4  
Role of Intellectual Property in U.S. Economy ............................................................................... 6  
Prevalence and Economic Consequences of IPR Infringement ....................................................... 8  
   Limitations on Data Estimating IPR Infringement Costs .......................................................... 8  
   International Economic Effects of IPR Infringement .................................................................. 10  
   U.S. Economic Effects of IPR Infringement ........................................................................... 11  
      Customs Seizure Data ............................................................................................................ 11  
      Economic Loss Estimates ..................................................................................................... 12  
The Organizational Structure of IPR Protection ............................................................................ 13  
   Multilateral IPR System ........................................................................................................... 13  
      World Trade Organization (WTO) ....................................................................................... 13  
      Declaration on TRIPS Agreement and Public Health ....................................................... 15  
      World Intellectual Property Organization (WIPO) ............................................................ 17  
   Free Trade Agreements ............................................................................................................ 18  
      Trade Promotion Authority and Negotiating Objectives ................................................... 18  
      IPR in Current Trade Negotiations ..................................................................................... 20  
      Central IPR Standards in U.S. FTAs .................................................................................... 22  
U.S. Trade Law .............................................................................................................................. 29  
   Special 301 ............................................................................................................................... 29  
   Section 337 ............................................................................................................................... 31  
   Generalized System of Preferences ......................................................................................... 32  
Issues for Congress ........................................................................................................................ 33  
   U.S. Efforts to Promote IPR Through Trade Policy ............................................................... 33  
   Addressing IPR Trade Challenges in Emerging Economies .................................................. 33  
   Effectiveness of the U.S. IPR Organizational Structure ......................................................... 35  
Looking Forward ........................................................................................................................... 36  

# Figures

Figure 1. Composition of U.S. Border Seizures of Counterfeit and Pirated Goods, FY2012 ............................................................. 11
Tables
Table 1. Global Intellectual Property Filings Through the PCT, 2010-2012 ........................................ 5
Table 2. Estimated International Economic Losses Due to Counterfeiting and Piracy, Selected Years ................................................................................................................................. 10
Table 3. Estimated U.S. Economic Losses Due to Counterfeiting and Piracy ............................... 12
Table 4. USTR 2013 Special 301 Report: Country Designations .................................................. 31

Appendixes
Appendix A. Summary of WIPO Treaties ........................................................................................ 37
Appendix B. Patent and Copyright Provisions in the TRIPS Agreement and U.S. FTAs .......... 39
Appendix C. Overview of IPR-Related U.S. Government Agencies and Coordinating Bodies ................................................................................................................................. 42

Contacts
Author Contact Information........................................................................................................... 47
Introduction

Intellectual property rights (IPR) traditionally have been matters of national concern. Individual nation states have developed IPR regimes reflecting their domestic needs and priorities. Over time, intellectual property protection and enforcement have come to the forefront as a key international trade issue for the United States—largely due to the importance of intellectual property as a prominent feature of an innovative U.S. economy—figuring prominently in the multilateral trade policy arena and in regional and bilateral U.S. free trade agreements (FTAs).

Congress has legislative, oversight, and appropriations responsibilities related to IPR and trade policy. The role of Congress in addressing IPR and trade-related issues stems from the U.S. Constitution, which provides Congress with the power “To promote the Progress of Science and useful Arts, by securing for limited Times to Authors and Inventors the exclusive Right to their respective Writings and Discoveries” and “To regulate Commerce with foreign Nations.” Congression interest has grown in the role of IPR in advancing U.S. industrial competitiveness and contributing to U.S. economic recovery following the recent international financial crisis. Some Members of Congress also have expressed concern about U.S. economic losses associated with IPR infringement; the potential health and safety consequences of counterfeit pharmaceutical drugs and other products; the national security implications of the theft of trade secrets, including through cybercrime; and connections between organized crime and IPR infringement.

This report discusses the different kinds of IPR and forms of IPR infringement; the role of IPR in the U.S. economy; estimated losses associated with IPR infringement; the organizational structure of IPR protection in multilateral, regional, bilateral arenas; U.S. government agencies involved with IPR and trade; and issues for Congress regarding IPR and international trade.

Intellectual Property Rights Basics

This section provides definitions of various kinds of intellectual property rights (patents, trade secrets, copyrights, trademarks, and geographical indications) and intellectual property rights misappropriation (infringement, piracy, and counterfeiting).

Types of IPR

IPR are legal rights granted by governments to encourage innovation and creative output. They ensure that creators reap the benefits of their inventions or works and may take forms such as patents, trade secrets, copyrights, trademarks, or geographical indications. Through IPR, governments grant a temporary legal monopoly to innovators by giving them the right to limit or control the use of their creations by others. IPR may be traded or licensed to others, usually in return for fees and/or royalty payments. Although the World Trade Organization (WTO) Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) provides minimum standards for IPR protections, such rights are granted on a national basis and are, in general, enforceable only in the country in which they are granted. However, countries are obliged to

1 U.S. Constitution, Article 1, Section 8.
abide by WTO rules, and their IPR enforcement practices can be challenged by other countries at the WTO.

**Patents**

The Patent Act (35 U.S.C. 101 *et seq.* ) governs the issuance and use of patents in the United States. Patents are granted for inventions of new products, processes, or organisms (known as utility patents). Patents also may be granted for designs and plants. For an invention to be patentable, it must be new, “non-obvious” (involving an inventive step), and have a potential industrial or commercial application. The patent provides the holder with the exclusive right to exclude others from making, using, selling, or importing into the United States the patented invention for a period of 20 years. The patent right is based on the proposition that inventors must be granted a temporary monopoly over their invention in order to encourage innovation and to promote the expenditure of money on research and development (R&D). The patent holder recoups these up-front costs through a temporary monopoly over the invention. In return for this economic rent, the patent holder must disclose the content of the patent along with test data and other information concerning the invention. This is meant to spur further creativity by those seeking to build on the patent after its expiration. Domestically, patents are granted by the U.S. Patent and Trademark Office (PTO) of the Department of Commerce.

**Trade Secrets**

A trade secret is any type of valuable information, including a “formula, pattern, compilation, program, device, method, technique, or process,” that derives independent economic value from not being generally known or readily ascertainable and is subject to reasonable efforts by the owner to maintain its secrecy. Examples of trade secrets include blueprints, customer lists, pricing information, and source code. While protection of patents and copyright is an exclusive matter of federal law, trade secret protection is found not only in federal law, but also in state law. Most states have adopted the Uniform Trade Secret Act (UTSA), a model law drafted by the National Conference of Commissioners on Uniform State Laws.

There are important differences between trade secrets and patents. Individuals do not have to apply for trade secret protection as they would for patents. Protection of trade secrets originates immediately with the creation of the trade secret; there is no process for applying for protection or registering trade secrets. Trade secret protection does not expire unless the trade secret becomes known. In contrast, patent applicants must disclose information about their innovation to the PTO in order to acquire a patent. Patents offer right holders stronger protection but for a limited period of time. While applying for a patent can be a costly and lengthy process, patents are valuable if the confidentiality of the innovation is fragile or if the area of research is highly competitive.

**Copyright**

Protection of copyrights in the United States is based on the Copyright Act (17 U.S.C. 101, *et seq.* ). Copyrights protect original expressions of authorship, fixed in physical and/or digital

---

2 In some cases, the effective duration of patent protection can be shorter, for example, because of regulatory delays in the approval of the patent or delays in obtaining marketing approval for the patented invention.

3 Uniform Trade Secret Act, §1(4).
forms. Such protections include literary or artistic works such as books, music, sound recordings, movies, paintings, architectural works, and computer software and databases (though not individual bits of data). Traditionally, copyrights differed from patents in that there was no claim to industrial applicability or novelty of the idea. The expression of the idea, not the underlying idea, was being copyrighted. While some of the criteria for copyrights differ from those of patents, the objective is the same: investments of time, money, and effort to create work of cultural, social and economic significance should be protected to encourage further creativity. U.S. law provides copyright protection for life of the author plus 70 years for personal works, or 120 years from creation (or 95 years from publication) for corporate works. Copyrights may be registered by the U.S. Copyright Office of the Library of Congress, although protection arises immediately upon fixation in a tangible medium of expression.

**Trademarks**

Trademark protection in the United States is governed jointly by state and federal law. The main federal statute is the Lanham Act of 1946 (15 U.S.C. 1051, et seq.). Also known as service marks, trademarks permit the seller to use a distinctive name, mark, symbol, or sound to identify and market a product, service, or company. The trademark allows quick identification of the seller’s product, and for good or ill, can become an indicator of a product’s quality. If for good, the trademark can be valuable in the introduction of new products by conveying an instant assurance of quality. The trademark is designed to prevent other companies with similar merchandise from free-riding on the association of quality with the trademarked item. Thus, a trademarked good may command a premium in the marketplace because of its reputation. For trademarks, distinctiveness is at a premium because a trademark must capture the consumer’s imagination to be effective as generic names of commodities cannot be trademarked. Trademark rights are acquired through use or through registration with the PTO.

A related concept to trademarks is the geographic indication, which is also protected by the Lanham Act. The geographic indication acts to protect the quality and reputation of a distinctive product originating in a certain region; however, the benefit does not accrue to a sole producer, but rather the producers of a product originating from a particular region. Geographic indications are generally sought for agricultural products, or wines and spirits. Protection for geographical indications is acquired in the United States by registration with the PTO, through a process similar to trademark registration. In general, however, the United States protects geographic indications through trademark law.

**Infringement of IPR**

IPR infringement is the misappropriation or violation of the IPR. In the case of patents, infringement of a patent owner’s exclusive rights (as afforded by patent laws) involves a third party’s unauthorized use of the patented invention. As relates to international trade, the greatest challenge to the patent right is infringement in foreign countries, or non-observance by WTO member states to the minimal standards of the TRIPS Agreement. Copyright infringement occurs when a third party engages in reproducing, performing, or distributing a copyrighted work without the consent of the copyright owner. In addition to the term infringement, other terms are used to describe certain violations of IPR.
Piracy

The term “piracy” has applications to both copyrights and trademarks. The major challenge facing copyright protection is piracy, either through physical duplication of the work, illegal dissemination of copyrighted material (such as computer software, music, or movies) over the Internet, and/or participation in commercial transactions of copyrighted materials without the consent of the copyright owner. With respect to trademarks, piracy involves the registration or use of a famous foreign trademark that is not registered in the country or is invalid because the trademark has not been used.

Counterfeiting

An imitation of a product is referred to as a “counterfeit” or a “fake.” Counterfeit products are manufactured, marketed, and distributed with the appearance of being the genuine good and originating from the genuine manufacturer. The purpose of counterfeit goods is to deceive consumers about their origin and nature. Counterfeiting and copying of original goods are major challenges for trademarked products. The counterfeited product can be sold for a premium because of its association with the original item, while reducing the sales of the original items. Furthermore, consumer experience with a counterfeited good of inferior quality, can damage the reputation of the trademark product. Popular examples of counterfeit products include fake fashionwear, such as Louis Vuitton bags or Rolex watches, or fake pharmaceutical products, such as popular brand-name prescription medicines.

A related issue is the imitation of labels and packaging of trademarked goods. In this situation, the imitator uses a trademark that is confusingly similar to a well-known trademark in order to benefit from the reputation of the product with which he is competing.

Innovation Indicators

According to the Organisation for Economic Co-operation and Development (OECD), innovation is the “implementation of a new or significantly improved product (good or service), or process, a new marketing method, or a new organizational method.” Innovation is widely considered to be a key source of economic growth, and IPR to be a major driver of innovation. The measurement of innovation is an evolving field. Possible elements of innovation indicators include activities related to the commercialization of inventions and new technologies. One such component could be global trends in patenting. Trends in the total number of patent filing applications received

---

4 Counterfeit goods should be distinguished from generic goods, i.e., in the case of generic forms of pharmaceutical medicines.
   
   Patenting is an intermediate step toward innovation, and patent data provide indirect and partial indicators of innovation. Not all inventions are patented, and the propensity to patent differs by industry and technology. Not all patents are of equal value, and not all foster innovation—patents may be obtained to block rivals, negotiate with competitors in infringement lawsuits.
under the Patent Cooperation Treaty (PCT), an international patent filing system administered by the World Intellectual Property Organization (WIPO), may be illustrative.

Between 2010 and 2012, the number of patents filed under the PCT grew by nearly 7% (see Table 1), reflecting economic recovery after the international financial crisis of 2008-2009. Intellectual property holdings that are protected by international agreements are highly concentrated in certain countries. The United States continues to be the source of the world’s largest number of patent filing applications under the PCT, representing close to one-third of such filings in 2012. The United States, along with Germany and Japan, accounted for about 60% of all patent applications filed in 2012 under the PCT. China ranked as the fourth largest source of international patent filings under the PCT in 2012, representing about 10% of global filings. In recent years, China has had the highest growth rate in such filings, at about 14% in 2012.

### Table 1. Global Intellectual Property Filings Through the PCT, 2010-2012

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>TOTAL</td>
<td>164,338</td>
<td>182,379</td>
<td>194,400</td>
<td>100.0%</td>
<td>6.6%</td>
</tr>
<tr>
<td>United States</td>
<td>45,029</td>
<td>49,060</td>
<td>51,207</td>
<td>26.3%</td>
<td>4.4%</td>
</tr>
<tr>
<td>Japan</td>
<td>32,150</td>
<td>38,874</td>
<td>43,660</td>
<td>22.5%</td>
<td>12.3%</td>
</tr>
<tr>
<td>Germany</td>
<td>17,568</td>
<td>18,851</td>
<td>18,855</td>
<td>9.7%</td>
<td>0.0%</td>
</tr>
<tr>
<td>China</td>
<td>12,296</td>
<td>16,402</td>
<td>18,627</td>
<td>9.6%</td>
<td>13.6%</td>
</tr>
<tr>
<td>South Korea</td>
<td>9,669</td>
<td>10,447</td>
<td>11,848</td>
<td>6.1%</td>
<td>13.4%</td>
</tr>
<tr>
<td>France</td>
<td>7,246</td>
<td>7,438</td>
<td>7,739</td>
<td>4.0%</td>
<td>4.0%</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>4,891</td>
<td>4,848</td>
<td>4,895</td>
<td>2.5%</td>
<td>1.0%</td>
</tr>
<tr>
<td>Switzerland</td>
<td>3,728</td>
<td>4,009</td>
<td>4,194</td>
<td>2.2%</td>
<td>4.6%</td>
</tr>
<tr>
<td>Netherlands</td>
<td>4,063</td>
<td>3,503</td>
<td>3,992</td>
<td>2.1%</td>
<td>14.0%</td>
</tr>
<tr>
<td>Sweden</td>
<td>3,314</td>
<td>3,462</td>
<td>3,585</td>
<td>1.8%</td>
<td>3.6%</td>
</tr>
<tr>
<td>Italy</td>
<td>2,658</td>
<td>2,695</td>
<td>2,836</td>
<td>1.5%</td>
<td>5.2%</td>
</tr>
<tr>
<td>Canada</td>
<td>2,698</td>
<td>2,945</td>
<td>2,748</td>
<td>1.4%</td>
<td>-6.7%</td>
</tr>
<tr>
<td>Finland</td>
<td>2,138</td>
<td>2,079</td>
<td>2,353</td>
<td>1.2%</td>
<td>13.2%</td>
</tr>
<tr>
<td>Australia</td>
<td>1,772</td>
<td>1,739</td>
<td>1,708</td>
<td>0.9%</td>
<td>-1.8%</td>
</tr>
<tr>
<td>Spain</td>
<td>1,772</td>
<td>1,729</td>
<td>1,687</td>
<td>0.9%</td>
<td>-2.4%</td>
</tr>
<tr>
<td>Others</td>
<td>13,346</td>
<td>14,298</td>
<td>14,466</td>
<td>7.4%</td>
<td>1.2%</td>
</tr>
</tbody>
</table>

**Source:** World Intellectual Property Organization.

---

Role of Intellectual Property in U.S. Economy

Intellectual property generally is viewed as a longstanding strategic driver of U.S. productivity, economic growth, employment, higher wages, and exports. It also is considered a key source of U.S. comparative advantage, such as in innovation and high-technology products. Nearly every industry depends on it for its businesses. Among the industries that are dependent on patent protection are the aerospace, automotive, computer, consumer electronics, pharmaceutical, and semiconductor industries. Copyright-based industries include the software, data processing, motion picture, publishing, and recording industries. Other industries that indirectly benefit from IPR protection include retailers, traders, and transportation businesses, which support the distribution of goods and services derived from intellectual property.8

IP-intensive industries are considered to play a major role in the U.S. economy and international trade. What follows are some findings from a study by the U.S. Department of Commerce.9

- **U.S. economic impact.** In 2010, a subset of the most intellectual property-intensive industries directly supported 27.1 million jobs in the United States, or about 18.8% of total U.S. employment. They also indirectly supported 12.9 million U.S. jobs via the supply chain in other industries. In 2010, the wages of employees working in IP-intensive industries tended to be about 42% higher on average than those working in non-IP-intensive industries. These industries accounted for $5.06 trillion in value added to the U.S. economy, more than one-third of the U.S. gross domestic product (GDP).

- **U.S. trade in goods.** In 2010, IP-related merchandise exports amounted to $775 billion (two-thirds of total U.S. merchandise exports), while IP-related merchandise imports reached $1,336 billion (about 70% of total U.S. merchandise imports). Key sectors for IP-intensive merchandise trade include semiconductor and electric parts, basic chemicals, motor vehicles, pharmaceuticals and medicine, and computer and peripheral equipment.10

- **U.S. trade in services.** In 2007, exports of services by IP-intensive industries totaled about $90 billion (about 19% of total U.S. private services exports). Key sources of services exports included the software publishing, motion picture and video, financial services, science R&D, and management and technical consulting industries. The study does not provide information on imports of services by IP-intensive industries, though it should be noted that the United States runs an overall surplus in international trade in services.11

---


10 It is important to note that trade statistics may not capture the full importance of intellectual property (IP)-intensive products to the U.S. economy, as many IP-intensive products are manufactured abroad as part of the global supply chain, and the full value added of these products is not accounted for in trade statistics. In addition, services statistics are limited.

The role of IP-intensive industries in U.S. trade in services includes receipts (exports) and payments (imports) of royalties and licensing fees. Right holders may authorize the use of technologies, trademarks, and entertainment products that they own to entities in foreign countries, resulting in revenues through royalties and license fees. In 2012, U.S. receipts from cross-border trade in royalties and license fees (relating to patent, trademark, copyright, and other intangible rights) totaled $124.2 billion, up about 3.5% from 2011 receipts of $120.7 billion. At the same time, U.S. payments of royalties and license fees to foreign countries amounted to $39.9 billion, up about 5% from the 2011 level of $34.8 billion. As with overall U.S. trade in services, U.S. cross-border trade in royalties and license fees generated a trade surplus—of $84.3 billion in 2012, a small decline from $85.9 billion in 2011. U.S. trade in royalties and licenses accounted for about 16% of total U.S. trade in private services in 2012.12

Industry-specific figures may further demonstrate the importance of intellectual property to the U.S. economy. For example:

- **Copyright industries.** According to a study commissioned by the International Intellectual Property Alliance (IIPA), in 2012, industries categorized as part of the “core” copyright industries (e.g., computer software, videogames, books, newspapers, periodicals and journals, motion pictures, recorded music, and radio and television broadcasting) contributed about $1 trillion to the U.S. economy (“value-added” to current GDP), representing about 6.5% of the U.S. economy. The study also estimated that the “core” copyright industries employed nearly 5.4 million workers in 2012, representing about 4% of the total U.S. workforce. In addition, the study estimated that foreign sales of certain U.S. copyright sectors totaled $142 billion in 2012.13

- **Pharmaceutical industry.** In 2012, domestic sales by pharmaceutical companies that are members of the Pharmaceutical Researchers and Manufacturers of America (PhRMA) reached an estimated $178 billion, while sales abroad by PhRMA members totaled about $117 billion.14

Some advocates of civil liberties assert that empirical analysis on the role of IPR in the U.S. economy may not be fully evaluating the economic and commercial benefits of lawful exceptions and limitations to exclusive rights. For example, by one estimate, businesses that rely on “fair use” exceptions to U.S. copyright law contribute $2.2 trillion to the U.S. economy. The “fair use” doctrine provides limitations and exceptions to the exclusive rights afforded by copyright law. It permits limited use of copyrighted works without requiring permission from the right holder in certain cases, examples of which may include news reporting, research, teaching, and library use.15

---

12 CRS analysis of data from BEA, U.S. International Services data.
Prevalence and Economic Consequences of IPR Infringement

Advances in information and technology and declining costs of transportation and communication, spurred by globalization, have fundamentally changed information and trade flows. Such changes have created new markets for U.S. exporters, but at the same time, have been associated with the proliferation of counterfeiting and piracy on a global scale.

Several factors contribute to the growing problem of IPR infringement. While the costs and time for research and development are high, IPR infringement occurs with relatively low costs and risks and a high profit margin. According to PhRMA, it takes a pharmaceutical company about 10 to 15 years of R&D to create a new drug, and the average cost to develop a drug in the early 2000s was about $1.2 billion, with costs possibly higher in more recent years. In 2012, PhRMA member companies collectively spent nearly $49 billion for research and development (domestic and abroad).\(^{16}\) In contrast, drug counterfeiters can lower production costs by using inexpensive, and perhaps dangerous or ineffective, ingredient substitutes.

The development of technologies and products that can be easily duplicated, such as recorded or digital media, also has led to an increase in counterfeiting and piracy. Increasing Internet usage has contributed to the distribution of counterfeit and pirated products. Additionally, civil and criminal penalties often are not sufficient deterrents for piracy and counterfeiting. The United States is especially concerned with foreign IPR infringement of U.S. intellectual property. Compared to foreign countries, IPR infringements levels in the United States are considered to be relatively low.\(^{17}\)

Limitations on Data Estimating IPR Infringement Costs

Quantification of the economic losses associated with IPR infringement has been a longstanding focus in the academic, policy, and industry literature. Many experts agree that it is difficult to quantify the magnitude of IPR theft with any precision. Reasons may include

- **Illicit nature of IPR infringement.** Because IPR infringement is illicit and secretive, tools that are used to measure legitimate business activity cannot necessarily be used to measure economic losses from IPR infringement. As such, it may be easier to quantify the positive contribution of copyright industries to the U.S. economy more precisely than to measure the losses to the U.S. economy from copyright piracy.

- **Quantifying specific components of economic impact.** The economic impact of IPR infringement depends on a range of factors, including the different types of infringing goods being sold, the rate at which consumers substitute buying infringing goods for legitimate goods, and IPR infringement’s deterrence to

\(^{16}\) PhRMA, 2013 Biopharmaceutical Research Industry Profile.

R&D. It may be difficult to measure precisely these components of the economic impact of IPR infringement.18

- **Assumptions used to calculate economic impact.** Methods for calculating data on counterfeiting and piracy often involve certain assumptions. Estimates of losses from IPR infringement can be highly sensitive to how these assumptions are derived and weighted. The basic economic model employed in some IPR loss estimates assumes that there is substitutability between pirated and legitimate goods. For example, under this model, sales of pirated goods may be equated to revenue losses of legitimate U.S. copyright businesses. Some analysts suggest that legitimate firms face a competition threat only if the individuals purchasing IPR-infringing products would be able and willing to purchase the legitimate product at the price offered when IPR infringement is not present.19 For consumers in poor developing countries, especially, this assumption may not be tenable.

- **IPR infringement in the digital environment.** While IPR infringement in the past primarily constituted counterfeiting and piracy of physical goods (such as optical media and books), in recent years, there has been a growing amount of piracy taking place through digital mediums (such as illegal downloads of music and books over the Internet). It may be more complex to measure IPR infringement that takes place in the digital environment, and in turn, more difficult to measure the associated economic losses accurately. U.S. trade losses due to copyright infringement may be higher than reported because estimates often do not account for all forms of piracy, such as Internet piracy, which is an increasingly significant contributor to copyright piracy. One study estimates that nearly 24% of global Internet traffic infringes upon copyright.20

- **Sources of data.** Estimates on economic losses from IPR infringement come from a range of sources, including academic, policy, and industry sources. According to a U.S. Government Accountability Office (GAO) study, the U.S. government does not systematically collect data or analyze the impacts of counterfeiting and piracy on the U.S. economy. In many cases, the federal government relies on estimates conducted by industry groups. However, companies may be reluctant to disclose their IPR losses because of possible reputational and commercial risks, and industry associations may not always release their proprietary data sources and methods, complicating efforts to verify such estimates.21

---

International Economic Effects of IPR Infringement

While assessments of the overall global economic costs of IPR infringement are limited, available evidence indicates that the adverse economic effects of global IPR infringement stand in the hundreds of billions of dollars, and are increasing. Customs data on seizures of counterfeit and pirated goods may offer some idea of the magnitudes involved in terms of impact on producers and exporters. A 2007 study by the Organisation for Economic Co-operation and Development (OECD) indirectly extrapolated available customs data on seizures to conclude that world trade in counterfeit and pirated goods may have amounted to $200 billion in 2005. Updated OECD estimates suggest that trade in IPR-infringing goods may have totaled up to $250 billion in 2007. During that same time period, the share of counterfeiting and pirated goods in world trade also is estimated to have increased—from 1.85% in 2000 to 1.95% in 2007.

More recently, a study commissioned by the Business Action to Stop Counterfeiting and Piracy (BASCAP), a business initiative organized by the International Chamber of Commerce, built on the OECD’s work. According to the BASCAP study, for the G-20 economies, the total value of counterfeit and pirated products was an estimated $455-$650 billion in 2008, and is projected to reach $1.22-$1.77 trillion in 2015 (see Table 2).

In terms of broader economy-wide effects, the BASCAP study estimated that G-20 economies lost $125 billion every year from counterfeiting and piracy due to additional impacts on trade, foreign investment, employment, and other factors. In addition, the study estimated that G-20 economies lost about 2.5 million jobs from counterfeiting and piracy; i.e., up to 2.5 million legitimate jobs could have been created in the absence of counterfeiting and piracy.

Table 2. Estimated International Economic Losses Due to Counterfeiting and Piracy, Selected Years

<table>
<thead>
<tr>
<th>Category</th>
<th>2008</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Internationally traded counterfeit and pirated products</td>
<td>$285-$360</td>
<td>$770-$960</td>
</tr>
<tr>
<td>Domestically produced and consumed counterfeit and pirated products</td>
<td>$140-$215</td>
<td>$370-$570</td>
</tr>
<tr>
<td>Digitally pirated products</td>
<td>$30-$75</td>
<td>$80-$240</td>
</tr>
<tr>
<td>Total</td>
<td>$455-$650</td>
<td>$1,220-$1,770</td>
</tr>
</tbody>
</table>


Notes: BASCAP economic loss estimates are restricted to the G-20 economies.

---

22 NIPRCC, 2011.
26 Ibid.
U.S. Economic Effects of IPR Infringement

While specific estimates vary, the available data suggest that U.S. economic losses from IPR infringement could be significant.

Customs Seizure Data

Data on pirated and counterfeit seizures of imports at U.S. borders shed light on the magnitude of the issue in the U.S. context (see Figure 1). The Department of Homeland Security (DHS) made 22,848 seizures of IPR-infringing goods in FY2012, down from 24,792 seizures in FY2011 but more than double the FY2005 level of 8,022 seizures. The general trend of the increased number of seizures over time could reflect a combination of increased DHS enforcement action and growing levels of counterfeiting and piracy. The total value of DHS seizures, as measured by the manufacturer’s suggested retail price (MSRP), amounted to $1.26 billion in FY2012, up from $1.11 billion in FY2011.\(^{27}\) It is worth noting that customs data may be limited in that they do not reflect digital-based IPR infringement.

**Figure 1. Composition of U.S. Border Seizures of Counterfeit and Pirated Goods, FY2012**

Of all U.S. trading partners, China continues to account for the majority of counterfeits intercepted at the U.S. border. In FY2012, seizures of goods originating from China represented 72% of all DHS seizures and $906 million in MSRP value. Other countries that were primary sources for counterfeit and pirated goods seized included Hong Kong, India, and Singapore.\(^{28}\)

---


A top priority for the CBP is seizing counterfeit imports that endanger the health and safety of consumers, such as counterfeit healthcare products, pharmaceutical products, and consumer electronics. The total MSRP value of IPR-related seizures of commodities that represent a potential safety and security risks was about $146 million (3,402 seizures) in FY2012, down from $196 million (4,369 seizures) in FY2011. Pharmaceutical goods were the top commodity category posing safety and security risks, accounting for more than half of such seizures by both MSRP value ($83 million) and number of seizures (2,343).29

Economic Loss Estimates

U.S. industries that rely on IPR protection claim to lose billions of dollars in revenue annually due to piracy and counterfeiting. Beyond these direct losses, the United States may face additional “downstream” losses from counterfeiting and piracy. IPR infringement could result in the loss of jobs that would have been created if the infringement did not occur, which could translate into lost earnings by U.S. workers and, in turn, lost tax revenues for federal, state, and local governments.30 Attempts have been made in specific economic sectors to quantify the IPR infringement levels and related losses to legitimate U.S. businesses.

Overall U.S. Estimates

The BASCAP study (discussed in the international section) used its global findings to determine the impact of global counterfeiting and piracy on the United States (see Table 3). BASCAP estimated that the United States consumes $66-$100 billion in domestically produced counterfeit and pirated goods annually (based on 2008 data). In terms of specific industries, BASCAP estimated that the United States consumes $7-$20 billion worth of digitally pirated recorded music and $1.4-$2 billion in digitally pirated movies in 2005.

<table>
<thead>
<tr>
<th>Category</th>
<th>Loss Estimate (based on 2008 data)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Internationally traded counterfeit and pirated products</td>
<td>$45-$60</td>
</tr>
<tr>
<td>Domestically produced and consumed counterfeit and pirated products</td>
<td>$12-$14</td>
</tr>
<tr>
<td>Digitally pirated products</td>
<td>$9-$25</td>
</tr>
<tr>
<td>Total</td>
<td>$66-$100</td>
</tr>
</tbody>
</table>


A private Commission on the Theft of American Intellectual Property estimates the total level of U.S. economic losses to international theft of U.S. intellectual property to be even higher, at

---

29 Ibid.

30 There may be limitations on data estimating the impact of counterfeiting and piracy on the U.S. economy. Some critics point out that many of the estimates for losses associated with IPR infringement are generated by industry groups that may have self-interested motivations.
hundreds of billions dollars per year. The Commission says the level of losses is comparable to the size of U.S. exports to Asia in 2012, valued at $320 billion.31

**Sectoral Estimates**

Attempts also have been made in some intellectual property-based industries to quantify the IPR infringement levels and related losses to legitimate U.S. businesses. For example, in prior years, IIPA, a U.S. copyright industry association, and PhRMA, a U.S. pharmaceutical industry association, have calculated estimates of losses to their member companies from IPR infringement. However, in recent years, neither of these industry groups has provided estimates. This may be, in part, because of the growing complexities in calculating the impact of such losses because of trends such as increased piracy taking place through the Internet.

**The Organizational Structure of IPR Protection**

Given the importance of intellectual property to the U.S. economy and the economic losses associated with counterfeiting and piracy, the United States is a leading advocate of strong global IPR rules. Since the mid-1980s, the United States has integrated IPR policy in its international trade policy activities, pursuing enhanced IPR laws and enforcement through multilateral, regional and bilateral trade agreements, and national trade laws.

**Multilateral IPR System**

**World Trade Organization (WTO)**

At the center of the present multilateral trading system is the World Trade Organization (WTO), an international organization established in 1995 as the successor to the General Agreements on Tariffs and Trade (GATT).32 The WTO was established as the result of the Uruguay Round of trade negotiations (1986-1994), which led to agreements to liberalize and establish or enhance rules on trade in goods, services, agriculture, and other non-tariff barriers to trade. One of the Uruguay Round agreements was the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement), which sets minimum standards on intellectual property rights protection and enforcement with which all WTO member states must comply. The United States, the European countries, and the IPR business community were instrumental in including IPR on the Uruguay Round agenda. Many developing countries were wary of including IPR in trade negotiations, preferring to discuss them under the World Intellectual Property Organization (WIPO) (see below) instead. However, developing countries agreed, after being granted delayed compliance periods, and after achieving negotiating goals on other issues such as the end of quotas on textiles and clothing.

While previous international treaties on IPR continue to exist, the TRIPS Agreement was the first time that intellectual property rules were incorporated into the multilateral trading system. Two basic tenets of the TRIPS Agreement are national treatment (signatories must treat parties of other

---


32 The GATT was originally established in 1947.
WTO members no less favorably in terms of IPR protection than the party’s own nationals) and most-favored-nation treatment (any advantage in IPR protection granted to the party of another WTO member shall be granted to nationals of all other WTO member states).

Much of the TRIPS Agreement sets out the extent of the agreement’s coverage of the various types of intellectual property: patents, copyrights, trademarks, trade secrets, geographical indications, industrial designs, layout of circuitry design, and test data. The TRIPS Agreement provisions build on several existing IPR treaties administered by the WIPO (discussed below). Another part provides standards of enforcement for IPR covered by the agreement. It enumerates standards for civil and administrative procedures and remedies, the application of border measures, and criminal procedures. A Council for the TRIPS Agreement was established to monitor the implementation of the agreement and transition arrangements were devised for developing countries. Finally, the agreement provides for the resolution of disputes under the Uruguay Round Agreement’s Dispute Settlement Understanding (see text box). The binding nature of the WTO dispute settlement mechanism, with the possibility of the withdrawal of trade concessions (usually the reimposition of tariffs) for non-compliance, sets this agreement apart from previous IPR treaties that did not have effective dispute settlement mechanisms.

**U.S. WTO Cases Against China on IPR**

In April 2007, the United States filed two WTO dispute settlement cases against China, alleging inadequacies in China’s enforcement of IPR laws and its barriers to market access for U.S. copyright businesses.33

In January 2009, the WTO issued its final ruling on the case centering on IPR enforcement issues. The WTO panel ruled in the United States’ favor that China’s denial of copyright protection to works without censorship approval is inconsistent with the TRIPS Agreement. The panel also agreed with the United States that it is impermissible for China to publicly auction IPR-infringing goods seized at the border, with the only requirement being that fake brands and trademarks be removed from the goods. The WTO panel ruled that more evidence was needed before deciding whether the thresholds for prosecution of counterfeiting and piracy in China’s criminal law permit commercial scale IPR infringement. China agreed to implement the WTO ruling.34

In August 2009, a WTO panel ruled that a number of China’s restrictions on trading rights and distribution of IPR-related products were inconsistent with WTO rules. However, the WTO panel did not address whether China’s censorship policies or import limitations on foreign films violate WTO rules. China agreed to implement the WTO ruling.35

The TRIPS Agreement also seeks a balance of rights and obligations between protecting private right holders and the obligation “to secure social and cultural development that benefits all.”36 Article 7 declares that

> ... the protection and enforcement of IPR should contribute to the promotion of technological innovation and to the transfer and dissemination of technology, to the mutual advantage of

---


producers and users of technological knowledge and in a manner conducive to social and
economic welfare and to a balance of rights and obligations.

This paragraph attempts to link the protection of IPR with greater technology transfer, including
technology covered by IPR protection, to the developing world. The language itself has been
interpreted in various ways. Developed countries have tended to consider this language
exhortatory, but developing countries have tried, without much success, to make technology
transfer a meaningful obligation within the TRIPS Agreement system. Article 66.2 of the
agreement requires developed country members to provide incentives to their enterprises and
institutions to promote technology transfer to least-developed countries to assist them in
establishing a viable technology base. Developed countries report annually on their efforts to
encourage technology transfer.

Complying with international IPR standards may impose greater burdens on developing countries
than developed countries. Developing countries generally have to engage in greater efforts to
bring their laws, judicial processes, and enforcement mechanisms into compliance with the
TRIPS Agreement. Consequently, developing countries were given an extended period of time in
which to bring their laws and enforcement mechanisms into compliance with the TRIPS
Agreement. Developing countries and post-Soviet states were given an additional four years from
the entry into force of the agreement (January 1, 1995). For products that were not covered by a
country’s patent system (such as pharmaceuticals in many cases), an additional five years was
granted to bring such products under coverage. For developing countries, all provisions of the
TRIPS agreement should now be in force. For the least developed countries, the phase-in period
for IPR commitments was originally extended 10 years to January 1, 2006 (Article 66.1). In 2002,
the WTO extended IPR obligations for least developed countries with respect to pharmaceuticals
to January 1, 2016.37 In addition, the WTO has extended the overall transitional period twice—in
2005, an extension to July 1, 2013, and then in 2013, a further extension to July 1, 2021.38 Article
66.1 acknowledges the:

special needs and requirements of least-developed country Members, their economic,
financial and administrative constraints, and their need for flexibility to create a viable
technological base.

Declaration on TRIPS Agreement and Public Health

In agreeing to launch the Doha Round of WTO trade negotiations, trade ministers adopted a
“Declaration on the TRIPS Agreement and Public Health” on November 14, 2001.39 The
Declaration sought to alleviate developing country dissatisfaction with aspects of the TRIPS
regime (see text box). It delayed the implementation of patent system provisions for
pharmaceutical products for least developed countries until 2016. The declaration committed
member states to interpret and implement the agreement to support public health and to promote
access to medicines for all. The Declaration recognized certain “flexibilities” in the TRIPS

37 “Extension of the Transition Period under Article 66.1 of the TRIPS Agreement for Least-Developed Country
38 WTO TRIPS Council, “Extension of the Transition Period Under Article 66.1 for Least Developed Country
Members,” June 12, 2013.
39 Declaration on the TRIPS Agreement and Public Health, (WT/MIN(01)/DEC/2), November 14, 2001, available at
http://www.wto.org/english/tratop_e/minist_e/min01_e/mindecl_trips_e.htm.
agreement to allow each member to grant compulsory licenses for pharmaceuticals and to determine what constitutes a national emergency, expressly including public health emergencies such as HIV/AIDS, malaria, and tuberculosis or other epidemics.

---

### Intellectual Property Protection and Development

The controversy over the relationship between IPR and development was engaged by the advent of the TRIPS Agreement, which for the first time placed IPR obligations on developing countries. Some hold that expansion of IPR is an obstacle to growth and development in less advanced countries, while others maintain that IPR are beneficial to both developed and developing countries.

Some IPR critics believe that a strong IPR regime may reduce developing countries’ access to technology from advanced countries by imposing relatively higher fees for technology licenses and production rights than would occur in the absence of IPR, limiting their innovation and economic growth and development. For instance, Japan, Singapore, Taiwan, and South Korea enhanced their technological abilities and developed their economies through “reverse engineering” of foreign technologies.

Others claim that IPR promote technology transfer through increased trade, foreign investment, and licensing in the long-run by making a country more attractive to foreign partners. A 2002 OECD study concluded that stronger IPR laws, particularly enhanced patent standards, may be associated with increased foreign direct investment (FDI) and trade for developing countries over time, with variation by industries and level of development. For instance, India experienced an increase in foreign investment and technology transfer once it expanded its patent protection. However, in recent years, India has taken measures considered by the U.S. government and business leaders to be a “backsliding” on IPR commitments, raising concerns about the country’s IPR and innovation environment. China offers a counterexample of a country that, despite some improvements, continues to have a weak IPR regime but high FDI and trade levels.

There is also evidence that IPR’s impact on developing countries may vary by the level of development. One study suggests that IPR protection may offer more benefits for the more industrialized developing countries, such as Brazil and India, compared to other developing countries. Such industrializing economies could experience economic growth of as much as 0.5% annually through increased trade, FDI, and licensing. Another study finds that rapid economic growth is associated with weak intellectual property regimes, but that developing countries with higher levels of per capita income may benefit economically from stronger IPR regimes.

There is also concern that strengthened patent protection may drive up prices for medicines or delay the entry of generic drugs into the market, reducing access to HIV/AIDS treatments and other drugs. IPR supporters argue that strong IPR is critical to creating incentives for pharmaceutical innovations and suggest that reduced prices are no guarantee that needed goods will make it into the hands of individuals in developing countries due to political corruption, poverty, lack of health care, and poor social infrastructure.

---

Paragraph 6 of the Doha Declaration directed the WTO members to formulate a solution to a corollary concern, the use of compulsory licensing by countries with insufficient or inadequate manufacturing capability. Compulsory licenses are issued by governments to authorize the use or production of a patented item by a domestic party other than a patent holder. They are authorized by Article 31 of TRIPS, which places certain limitations on their use, scope, and duration. A provision that predominantly restricted production authorized by compulsory license to the

---

40 Compulsory licenses are issued by governments to authorize the use of or production of a patented item by a domestic party other than a patent holder.


domestic market became the focal point of the negotiations because it, in effect, conveys the right of compulsory licensing only to countries with the capability to manufacture a given product. Countries without a domestic manufacturing capability were essentially precluded from using this flexibility of the TRIPS agreement.

On the eve of the Cancun Ministerial in August 2003, WTO members agreed on a Decision\(^4^4\) to waive the domestic market provision of the TRIPS article on compulsory licensing (Article 31(f)) for exports of pharmaceutical products for “HIV/AIDS, malaria, tuberculosis and other epidemics” to least developed countries and countries with insufficient manufacturing capacity. This Decision was incorporated as an amendment to the TRIPS agreement at the Hong Kong Ministerial in December 2005.

The amendment must be ratified by two-thirds of the 153 WTO member states. The deadline for ratification has been extended a number of times, most recently, until December 31, 2015.\(^4^5\) Until then, the 2003 waiver continues in force. To date, the United States and 76 other WTO members have ratified the amendment.\(^4^6\) This means another 25 countries must ratify the amendment to reach the two-thirds threshold.

The system established by the WTO allows least developed countries and countries without sufficient manufacturing capacity to issue a compulsory license to a company in a country that can produce such a product. After a matching compulsory license is issued by the producer country, the drug can be manufactured and exported subject to various notification requirements, as well as quantity and safeguard restrictions. While several exporting countries have established laws and procedures for implementing this system, only Rwanda has availed itself of the system to import HIV/AIDS medicines from a generic manufacturer in Canada.\(^4^7\)

**World Intellectual Property Organization (WIPO)**

In addition to the WTO, the other main multilateral venue for addressing IPR issues is the World Intellectual Property Organization (WIPO), a specialized agency affiliated with the United Nations with its own executive, legislative, and budgetary powers. Established in 1970, following the entry into force of the 1967 WIPO Convention, WIPO is charged with fostering the effective use and protection of intellectual property globally. WIPO’s mandate focuses exclusively on intellectual property, in contrast to the WTO’s broader international trade mandate. WIPO’s antecedents are the 1883 Paris Convention for the Protection of Industry Property and the 1886 Berne Convention for the Protection of Literary and Artistic Work. Most of the substantive provisions of these two treaties are incorporated in the WTO’s TRIPS Agreement. WIPO’s primary function is to administer a group of IPR treaties which put forth minimum standards for

---


member states (see Appendix A). All international IPR treaties, save TRIPS, are administered by WIPO.

In order to address digital technology issues not dealt with in the TRIPS Agreement, WIPO established the WIPO Copyright Treaty (WCT) and WIPO Performance and Phonograms Treaty (WPPT) in 1996, oftentimes collectively referred to as the “WIPO Internet Treaties.” Recent WIPO efforts have focused on patent law. In June 2000, WIPO signatories adopted the Patent Law Treaty (PLT), which called for harmonization of patent procedures. This agreement went into force on April 28, 2005. Discussions began in May 2001 for the Substantive Patent Law Treaty (SPLT), which targets issues specifically related to patent grants, but were put on hold in 2006. Government leaders participating in the Group of 8 (G-8) meeting in July 2008 called for “accelerated discussions” of the SPLT. While discussions remain stalled, the main focus of the WIPO’s work in this area has been on “building a technical and legal resource base from which to hold informed discussions in order to develop a work program” on various patent issues.

WIPO’s other functions include assisting member states through training programs, legislative information, intellectual property institutional development, automation and office modernization efforts, and public awareness activities. WIPO’s enforcement activities are more limited than those of the WTO. Through its Advisory Committee on Enforcement (ACE), WIPO cooperates with member states to promote international coordination on enforcement activities.

Free Trade Agreements

In recent years, the United States increasingly has focused on free trade agreements (FTAs) as an instrument to promote stronger IPR regimes by foreign trading partners. In general, the United States has viewed the TRIPS Agreement and WIPO-administered treaties as a minimum standard and has pursued higher IPR protection and enforcement levels through regional and bilateral FTAs. To date, the United States has entered into 14 FTAs with 20 countries.

Trade Promotion Authority and Negotiating Objectives

Under Trade Promotion Authority (TPA), Congress delegates its constitutional authority to regulate foreign commerce to the President to negotiate and enter into certain free trade agreements (FTAs). TPA also includes provisions allowing implementing bills for trade agreements to be considered under expedited legislative procedures (no amendment, up-or-down vote), provided the President follows the guidelines, negotiating objectives, reporting, and consultation requirements mandated by Congress. IPR issues have become important negotiating objectives in grants of TPA; the most recent extension of that authority expired on July 1, 2007.

---

48 These WCT and WPPT frequently are referred to as the WIPO Internet Treaties.
51 See CRS Report RL33743, Trade Promotion Authority (TPA) and the Role of Congress in Trade Policy, by William H. Cooper.
IPR negotiating objectives for FTAs were first enacted in trade promotion authority (then known as fast-track authority) by the Omnibus Trade and Competitiveness Act of 1988 (P.L. 100-418). The act sought enactment and enforcement of adequate IPR protection from negotiating partners. It also sought to strengthen international rules, dispute settlement, and enforcement procedures through the GATT and other existing intellectual property conventions. This negotiating mandate led to the establishment of the TRIPS Agreement during the Uruguay Round and the IPR provisions in the North American Free Trade Agreement (NAFTA). In the period since the 1988 Act, the IPR provisions of NAFTA and the TRIPS agreement became the template for other bilateral or regional FTAs. Thus, the focus of IPR negotiating objectives shifted from creating to strengthening the IPR trade regime.

2002 Trade Promotion Authority

FTA negotiations concluded under the George W. Bush Administration were conducted under the Trade Promotion Authority Act of 2002 (P.L. 107-210). The principal negotiating objectives with regards to IPR included

- Furthering adequate and effective protection of IPA through accelerated and full implementation of the TRIPS agreement and by ensuring FTAs negotiated by the United States “reflect a standard of protection similar to that found in U.S. law”\(^{52}\);
- Protecting IPR related to new technologies and distribution methods, and facilitating legitimate digital trade;
- Eliminating discriminatory treatment in the use and enforcement of IPR;
- Ensuring adequate rights holder protection through digital rights management practices; and
- Providing strong enforcement of IPR.

These IPR negotiating objectives were highly significant to the future contours of U.S. FTA negotiations. The objective to negotiate trade agreements in terms of IPR that “reflect a standard of protection similar to that found in U.S. law”\(^{52}\) led to the negotiation of provisions that go beyond the level of protection provided in the TRIPS agreement. Often referred to as “TRIPS-plus” provisions, these obligations include expanding coverage to new sectors; establishing more extensive standards of protection; and reducing the flexibility options available in TRIPS, such as with respect to compulsory licensing. Some of the new measures also address technological innovations that have come about since the TRIPS Agreement.

The objective to apply existing IPR protections to digital media reflected the changing nature of global commerce. The language sought to extend provisions for IPR protection to new and emerging technologies and methods of transmission and dissemination. The language also called for standards of enforcement to keep pace with technological change and allow right holders legal and technological protections for their works over the Internet and other new media.

---

52 P.L. 107-210, Sec. 2102(b)(4).
May 10, 2007, Bipartisan Trade Agreement

On May 10, 2007, the Bush Administration and Congress concluded a bipartisan agreement on trade policy that addressed some Members’ concerns about the implications of enhanced IPR on developing countries’ ability to meet public health needs (commonly referred to as the “May 10th Agreement”). In particular, congressional leadership sought to ensure that pending FTAs allowed trading partners enough flexibility to meet their IPR obligations and to be able to promote access to life-saving medicines, while otherwise meeting their international IPR protection and enforcement obligations. IPR language previously negotiated in the FTAs with the developing countries of Peru, Panama, and Colombia subsequently was modified to reflect the agreement. Because South Korea is an industrialized country, the United States did not significantly scale-down the patent protection obligations in the U.S.-Korea FTA.

Possible TPA Renewal

TPA in the form of the Bipartisan Congressional Trade Priorities Act of 2014 (BCTPA) (H.R. 3830/S. 1900) was introduced on January 9, 2014. The principal negotiating objectives in BCTPA with regards to intellectual property rights are similar to those of the TPA in 2002 (see above).

In addition, a new objective in the proposed BCTPA seeks to negotiate the prevention and elimination of government involvement in violations of IPR such as cybertheft or piracy. A related protection of trade secrets and proprietary information collected by governments in the furtherance of regulations are contained in the negotiating objective on regulatory coherence.

Finally, the proposed legislation reaffirms the Declaration on the TRIPS Agreement and Public Health and adds language to “foster innovation and access to medicine.” It does not specifically refer to the patent protection provisions found in the May 10, 2007, Bipartisan Trade Agreement (discussed above) and the added language seemingly could be used to justify including or excluding those provisions in future FTAs.

IPR in Current Trade Negotiations

Trans-Pacific Partnership FTA

The Obama Administration is conducting negotiations with participants in the Trans-Pacific Partnership (TPP) Agreement—Australia, Brunei, Canada, Chile, Japan, Malaysia, Mexico, New Zealand, Peru, Singapore and Vietnam. The objective is to build a comprehensive, high-standard reciprocal agreement to reduce and eliminate trade barriers and establish rules and disciplines to govern trade and investment in the region, and to expand and strengthen U.S. economic ties with other participating countries in the region. Through the TPP, the United Seeks to build on already established FTAs with Australia, Canada, Chile, Mexico, Peru, and Singapore.


The United States is negotiating strong IPR provisions in the TPP consistent with the TPA mandate to “reflect a standard of protection similar to that found in U.S. law.” On the controversial issue of additional patent protection for pharmaceuticals (e.g., patent term extension, patent linkage, data protection), the United States reportedly has offered a plan similar to the May 10th provision: to allow for optional implementation for developing countries in the TPP and mandatory provisions for developed ones, although certain details have yet to be worked out.\textsuperscript{55}

IPR reportedly has been one of the more controversial chapters in the TPP negotiating text. Significant disagreement reportedly continues to exist between and among the parties negotiating the TPP such as in the areas of:

- **Copyrights:** Debate over the extension of copyright term lengths, protection of temporary copies, fair use provisions, Internet services provider liability, and anti-circumvention protection;

- **Patents:** Debate over the ability to patent plants and animal life, the ability to patent new uses for an existing product (e.g., “evergreen” patents), and data exclusivity for biologics, among other issues; and

- **Enforcement:** Debate over criminal penalties for trademark counterfeit and copyright piracy, as well as \textit{ex officio} powers to seize suspected counterfeit goods in transit.\textsuperscript{56}

**Transatlantic Trade and Investment Partnership FTA**

The Obama Administration also is conducting negotiations with the European Union (EU) on a comprehensive and high-standard free trade agreement, referred to as the proposed Transatlantic Trade and Investment Partnership (TTIP).\textsuperscript{57} The United States and EU both maintain strong IPR standards and generally prioritize IPR protection and enforcement as a key trade negotiating objective. However, a final report by the U.S.-EU High Level Working Group on Jobs and Growth, which recommended the launch of the transatlantic FTA negotiations, suggested that it may be difficult to reconcile differences on the IPR obligations that each side typically includes in its FTAs.\textsuperscript{58} For example, protection and enforcement of geographical indications could be controversial in the negotiations. The EU seeks strong GI protection because of their commercial value to EU producers (e.g., Parmesan cheese, Parma ham, Feta cheese, and Champagne). The United States tends to protect GIs through trademark law, and expresses concern that the EU


approach to GIs raises national treatment issues and adversely affects trademarks and widely accepted generic products.\textsuperscript{59}

Stakeholders on both sides could raise issues about how to balance IPR protection and enforcement with other public policy goals, such as access to medicines in poor or developing countries and the free flow of information. At the same time, the TTIP could lead to rules on trade secrets, an area of U.S. and EU concern in light of increased instances of trade secret theft internationally, including through cybercrime.\textsuperscript{60}

\textbf{Anti-Counterfeiting Trade Agreement}

The Anti-Counterfeiting Trade Agreement (ACTA), which was negotiated outside of the WTO by the United States and nearly 40 other primarily developed countries, is intended to build on the TRIPS Agreement, such as by addressing new IPR issues in the digital environment. Concluded in 2010, the ACTA has not entered into force. The agreement’s prospects are in question, following the European Parliament’s rejection of it in 2012, amid widespread protests by advocates of Internet free speech. The ACTA needs instruments of ratification, acceptance, or approval from six signatories in order to enter into force. To date, Japan is the only party that has submitted a formal instrument of approval. IPR issues considered in the ACTA negotiations have reemerged in in the TPP and TTIP negotiations, making the ACTA of continued congressional interest.

\textbf{Central IPR Standards in U.S. FTAs}

What follows is a discussion of some of the central patent and copyright standards sought in FTAs that are currently in force or have been signed by the United States (see \textit{Appendix B}).\textsuperscript{61}

\textbf{Patents}

Patent protection is arguably one of the most contentious areas of U.S. FTA negotiations on IPR issues. While the United States and other developed countries advocate for strong patent protections in order to promote innovation, there is concern that such stringent protections may delay developing countries’ access to, and increase prices of, generic drugs. Other issues also have emerged in patent debates, such as with respect to the patentability of innovations related to plants and animals (see \textbf{text box}). Many of the FTAs in force include TRIPS-plus patent provisions, the most prominent of which are patent term length extensions, linkages between regulatory authority and patent status, data protection, compulsory licensing and parallel importation. The FTAs with Peru, Panama, and Colombia respond to the concerns of some Members of Congress over provisions that could restrict access to medicines in these countries


\textsuperscript{61} For a more detailed discussion of the differences between the TRIPS Agreement and regional FTAs that are in force, see CRS Report RL33205, \textit{Intellectual Property and the Free Trade Agreements: Innovation Policy Issues}, by John R. Thomas.
and contain less ambitious standards for pharmaceutical patents, compared to previously negotiated FTAs. Pharmaceutical industry advocates express concern that this modification in patent protection in these FTAs may set a precedent for future FTA negotiations. How these issues will be addressed in the proposed TPP and TTIP continue to evolve. Some key patent issues are discussed below.

**Patent Term Extensions.** Many FTAs include provisions for mandatory patent term length extensions beyond the TRIPS Agreement obligation of patent protection terms of twenty years from the filing date. These FTAs allow for extensions in cases of “unreasonable” delays in the issuance of patents due to regulatory review or administrative process, which lessen the effective 20-year term of patent protection. Patent holders contend that such measures enhance the ability of rights-holders to recoup the costs of research and development of new products. However, there is concern that patent term extensions may delay the entry of generic drugs into a market. In a modification of TRIPS-plus obligations, FTAs with Peru, Colombia, and Panama state that patent term restorations for pharmaceutical products are optional.

**Patent Linkages.** Patent linkage is a common provision in the trade agreements obtained by the United States. In general, the term “patent linkage” refers to the attachment of regulatory approval for the marketing of a drug with the status of a patent. If a patent exists, the Food and Drug Administration and its counterparts in other countries may not grant marketing approval for a generic version of a drug that is patented in the country without the permission of the patent holder. The notion of patent linkage presents a departure from the minimum standards under TRIPS, under which generic drug manufacturers are able to apply for marketing approval without the patent owner’s permission and prior to the expiration of the patent; this may reduce the time it takes for generic drugs to enter a market once the patent expires. In light of developing country concerns about delays in access to generic versions of drugs, FTAs signed with Peru, Panama, and Colombia do not tie marketing approval for a generic drug with the patent status of its brand name drug.

**Data Protection.** In cases in which the patent holders must submit undisclosed data regarding the safety or efficacy of new pharmaceutical or agricultural products (such as data from clinical trials) in order to market them, the TRIPS Agreement requires members to take measures to protect such data from disclosure and unfair commercial use. The TRIPS Agreement does not prescribe any time period for this protection. Recent U.S. FTAs generally require a five-year period of marketing exclusivity for the patent holder, which typically begins from the date the product is approved in the country. Under this TRIPS-plus provision, generic drug manufacturers who want to market and distribute a generic version of a drug while the data exclusivity period is in effect must conduct their own clinical trials and submit their own findings to the national drug regulatory authority; they cannot rely on the findings submitted by the patent holder. On one hand, clinical trials and other testing used to develop the data submitted for marketing approval can be costly and take years to develop, and thus, adequate protection of test data is important as an incentive for future investments in such R&D. On the other hand, such provisions may raise the cost of manufacturing generic versions of patented drugs, as well as delay access to generic

---


63 While TRIPS does not directly speak to the rights of generic drug manufacturers in obtaining marketing approval for a generic drug before the expiration of the patented drug, Article 30 of TRIPS permits exceptions of patent rights for activities such as “research, prior user rights, and pre-expiration testing.”
forms of drugs. The FTAs with Peru, Panama, and Colombia include provisions that may reduce data exclusivity terms of five years by a minimum of six months in practice.  

**Compulsory Licensing.** A compulsory license is an authorization by a government for third parties (such as a company or the government itself) for the manufacture or use of a product under patent without the permission of the rights-holder. The TRIPS Agreement permits signatories to issue compulsory licenses for patented devices and provide compensation to the owner of the patent and does not limit the situations in which such licenses may be issued. The third party must have attempted to obtain permission from the patent holder, although this requirement is waived in times of national emergency or other extenuating circumstances. U.S. FTAs with Australia and Singapore limit attaining compulsory licenses only for domestic use and to situations of remedying antitrust violations or in situations of public non-commercial use, national emergency, or other cases of extreme need. Also under these FTAs, the patent holder is under no obligation to provide test data, technical know-how or other undisclosed information for the patent subject to compulsory license. The compulsory license provisions have not been included in FTAs with developing countries. In addition, the U.S.-Korea FTA (KORUS) does not place any specific limitations on compulsory licensing.

**Parallel Importation.** Parallel imports, also known as grey-market goods, refer to goods imported into a country without permission of the rights-holder after those goods were legitimately sold elsewhere. Parallel importation relates to the concept of territorial exhaustion of IPR, which governs the extent of IPR after the first sale. Under a national system of exhaustion practiced in the United States, IPR are exhausted domestically after the first sale, but not abroad, thus prohibiting trade in those goods without permission of the rights-holder. Under an international system, IPR are exhausted at the first sale for any destination, and such goods can be exported freely. Article 6 of the TRIPS specifically excludes issues arising from exhaustion of IPR from WTO dispute settlement, allowing each member to adopt different exhaustion regimes. Thus, TRIPS does not address the issue of parallel imports. Some developing countries contend that parallel importation is an alternative method for governments to increase access to medicines in the absence of a compulsory license. Pharmaceutical companies have voiced concerns that this practice threatens their ability to engage in price differentiation between different markets. U.S. FTAs negotiated with Australia, Singapore, and Morocco disallow parallel importing of patented products. Subsequent U.S. negotiated FTAs have not included this provision, due to language included in the Science, State, Justice, and Commerce, and Related Agencies, Appropriations Act of 2006 (P.L. 109-108), which prohibited the use of such provisions.

---

64 For example, under the Peru FTA, if a company files to market a new drug in Peru after making an initial filing in another country, such as the United States, and Peru approves the drug within six months of the filing, the data exclusivity period begins at the time the drug was approved in the country of the initial filing, not Peru.

Biodiversity and Traditional Knowledge

International trade negotiations increasingly have focused on the protection of plant and animal inventions, new plant varieties, traditional knowledge, and folklore. Some indigenous communities in developing countries and international non-governmental organizations have expressed concern about the use of patents to provide private rights for traditional knowledge and genetic material; the commercial use of such resources by entities other than the indigenous communities or countries from which such resources are derived; and the distribution of benefits from commercial use. The United States, other advanced countries, and business groups favor treating traditional knowledge and genetic material as intellectual property and protecting these resources through an IPR framework.

Article 27.3(b) of the TRIPS Agreement permits Member states to exempt “plants and animals other than microorganisms, and essentially biological processes” from patentability. TRIPS requires Members to protect plant varieties through patent protection, some other system ("sui generis"), or a combination of the two. Paragraph 19 of the Doha Declaration added another dimension to the issue by requiring the TRIPS Council to probe the relationship between the TRIPS Agreement, the UN Convention on Biological Diversity (CBD), and traditional knowledge and folklore. These issues also are being discussed in WIPO’s Intergovernmental Committee on Intellectual Property and Genetic Resources, Traditional Knowledge, and Folklore (IGC).

India, Brazil, and Peru, among other countries, contend that patent applicants should be required to disclose the source of genetic materials, including plant life and traditional knowledge, before obtaining patents. The United States and the European Union have advocated for national systems in which companies are granted permission to research genetic materials and are obligated to share benefits from patents derived from those genetic products.

Some earlier U.S. FTAs have required signatories to provide protection for plants, animals, and plant varieties. The recent FTAs with Peru, Panama, and Colombia do not mandate patentability for plants and animals, but state that the countries should take efforts to expand patent coverage to these areas and to maintain this protection once it is offered. Side-letters in the three FTAs state the signatories’ recognition of the importance of biodiversity and traditional knowledge and pledge the countries to work together to address these issues through the IGC.

Copyright

In the area of copyright protection, the United States has pursued certain TRIPS-plus measures in FTAs, such as extending copyright terms; including anti-circumvention provisions; and protecting rights-management information in its FTAs. The TRIPS Agreement does not mention any obligations regarding rights-management information, which is “electronic information that identifies a protected work, its author, and terms and conditions of use,” perhaps due to the fact these technologies were not available at the time. In contrast, U.S.-negotiated trade agreements prohibit the removal or alteration of such information.

While patent protection has experienced policy shifts in the FTAs with Peru, Panama, and Colombia, copyright protection provisions have remained fairly consistent through the FTAs. In general, FTA signatories are obligated to provide an additional twenty years of copyright protection. This brings the minimum copyright term to seventy years from the death of the author or authorized publication, compared to fifty under the TRIPS Agreement. Responding to technological innovations not discussed in the TRIPS Agreement, many of the FTAs require trading partners to outlaw circumvention of technological measures protecting access to copyrighted works. These provisions build on the U.S. Digital Millennium Copyright Act (DMCA) of 1998. Also based on the DMCA, many FTAs contain provisions that regulate the liability of Internet service providers (ISPs) for copyright infringement that occurs within their


67 The DMCA (P.L. 105-304) prohibits disabling technological protection measures designed to protect copyright works through activities such as descrambling or decrypting copyrighted works.
networks. Under the FTAs, ISPs are provided limited immunity from copyright liability in certain kinds of infringing activities if they comply with regulations. For instance, ISPs must block access to or remove infringing materials as soon as they are aware of the infringement. Copyright holders argue that it is necessary for ISPs to assist in enforcing copyright for copyright laws to be effective. However, critics claim that these provisions impose excessive burdens on ISPs, reduce the rights of Internet users, and limit the policy flexibility of FTA signatories in determining their own IPR regimes.

**Trade Secrets**

A company’s ability to protect its commercially valuable proprietary information may affect its competitiveness or even its survival. Such proprietary information can include blueprints, production processes, marketing strategies, or sales information. In its 2013 Special 301 Report (discussed below), USTR described the protection of U.S. trade secrets as a growing challenge threatening the economic security of the United States. The report responded to concerns of U.S. business that governments have pressured them to reveal trade secrets or to transfer technology to further a country’s ‘indigenous innovation’ policies. Companies are also reportedly increasingly victimized by outright theft of their trade secrets, and have decried the often lax remedies available to combat such theft. Trade secret theft has taken on new and increased complexities in the digital environment, and the United States is increasingly concerned about trade secret theft through cybercrime. Penalties for trade secret theft vary widely among countries; some countries have no penalties at all while others have civil remedies or criminalize trade secret theft that results from computer hacking. In the United States, remedies for trade secret theft primarily are found in state law.68

While the U.S. aim in the intellectual property chapters of the TPP seeks to establish criminal penalties for the theft of trade secrets, it may pursue aspects of this agenda through other trade negotiations or means of economic statecraft. Such an agenda may involve prohibiting countries from: (1) conditioning market access on technology transfer; (2) seeking concessional terms for acquiring or licensing IPR by state-owned enterprises (SOEs); (3) requiring the use of locally owned or developed IPR; (4) promoting the development of local standards to unfairly advantage local firms; and (5) requiring the unnecessary disclosure of confidential business information, or failing to protect such information. The Obama Administration’s strategy on mitigating the theft of U.S. trade secrets, released in February 2013, underscores U.S. interest in seeking, in U.S. trade negotiations, new criminal remedy provisions for trade secret theft—similar to remedies provided in U.S. law.69

**New and Evolving Issues**

U.S. trade policy also increasingly is focused on addressing new and evolving issues in international IPR protection and enforcement. The IPR landscape is changing, both due to the growing role of emerging markets in the global marketplace and the increased level of

---


international trade taking place in the digital environment. Some of these issues are discussed below.

**Indigenous Innovation.** Originally associated with China, “indigenous innovation” is a term that can reflect multiple policy goals, including promoting innovation from domestic companies rather than relying on foreign technology, building domestic R&D capabilities, and increasing the share of overall value added by domestic companies to the domestic economy. Such innovation policies can surface in areas such as government procurement, technical standards, and technology transfer. For example, indigenous innovation policies may require the transfer of technology as a condition for allowing access to a market or for a company to continue to do business in the market. While the goal of increasing domestic manufacturing and innovation is understandable, the U.S. government, industry groups, and other stakeholders express concern that indigenous innovation policies are discriminatory and may unfairly disadvantage U.S. right holders in those countries. China’s indigenous innovation policies, for example, have been a source of trade tension with the United States. Although the Chinese government has pledged to separate indigenous innovation from government procurement, U.S. business leaders remain concerned that China’s policies may lead to discrimination against foreign firms or run afoul of WTO commitments. While China’s indigenous innovation policies remain a focal point of U.S. trade policy, according to the USTR’s 2013 Special 301 Report, such policies appear to be gaining ground in other countries as well, such as India.

**Localization Barriers to Trade.** Functioning as a type of non-tariff barrier to market access, “forced” localization measures generally refer to those designed to protect, favor, or stimulate domestic industries, service providers, or intellectual property at the expense of foreign counterparts. Localization barriers can take a number of forms, such as requirements for: service providers to process data in the foreign country as a condition of market access; businesses to transfer technology and intellectual property as a condition of approval of foreign investments; or firms to use local content as a condition for manufacturing or for government procurement. For example, in November 2011, India issued a “National Manufacturing Policy,” which calls for greater local content requirements in government procurement in certain sectors, such as information and communications technology and clean energy. India’s National Manufacturing Policy is rooted in the country’s goal of developing its manufacturing base and boosting employment. Based on this policy, in recent years, the Indian government has undertaken or is considering undertaking a series of regulatory measures mandating the use of local goods and services in business activity in India, across a range of industrial sectors. While some localization barriers may serve data privacy or security objectives, concerns have arisen that some of these measures can be economically distorting. According to the USTR, these measures can distort trade, inhibit FDI, and lead other countries to follow suit. Certain localization barriers have been addressed in previous multilateral trade negotiations. For instance, the WTO Agreement on Trade-Related Investment Measures (TRIMs) prohibits “local content” requirements imposed in a discriminatory manner with respect to foreign investment.

---

70 The term “indigenous innovation” can be tied to China’s Medium- to Long-term Plan for the Development of Science and Technology, released in January 26, which calls for China to become an “innovation-oriented society” and a global leader in science and technology.


72 For more information, see CRS Report RL33536, *China-U.S. Trade Issues*, by Wayne M. Morrison.


74 As defined by USTR, “local content” requirements are requirements to purchase domestically-manufactured goods (continued...
particularly with respect to the digital environment, are considered to be newer trade issues, and are a focus of the TPP and TTIP negotiations.

**Patent Revocation, Denial and Changes in Thresholds of Patentability.** U.S. policymakers, business leaders, and other are increasingly concerned about policy and legal developments in various countries that, from their perspective, are leading to a deterioration of patent protections. Key issues have been raised about provisions in India’s Patent Law that prohibit patents on certain chemical forms absent a showing of increased efficacy. According to the USTR, this practice could limit the patentability of potentially beneficial innovations (see text box).

---

**Recent Pharmaceutical Patent Decisions in India**

Since 2012, India has denied or revoked patents for several cancer and hepatitis C drugs developed by several Western pharmaceutical companies, including Bayer, GSK, Novartis, Pfizer, and Roche. India’s Supreme Court has decided to prohibit patents for certain chemical forms absent a showing of “enhanced efficacy,” although the products are protected by patents in many other countries. India’s patent laws are designed to protect against “ever-greening,” a practice by which an innovator pharmaceutical company seeks a patent on a modified version of the originally patented drug to extend the life of the patent, unless there is a showing of enhanced efficacy. Some argue that through ever-greening, pharmaceutical companies make minor modifications to their patents solely to extend their monopoly on the patent, thus, delaying the entry of lower-cost generic versions of the drugs onto the market. Others argue that the modifications can provide new benefits, such as “fewer side effects, decreased toxicity, and better delivery systems.”

India also has issued, or threatened to issue, compulsory licenses for pharmaceuticals. For example, in March 2012, the Indian government issued a compulsory license to an Indian pharmaceutical company to produce a generic version of Nexavar, a kidney cancer drug produced by Bayer. India defended its decision on the basis that the price for the patented drug was too high for most Indians. In other developments, the Indian government “hinted” it would revoke the patent on Herceptin, a breast cancer drug developed by Roche. In August 2013, Roche withdrew the patent for the drug in India.

Another country of concern is Canada. The USTR noted concerns about Canadian courts’ recent decisions regarding the heightened “utility” requirement for pharmaceutical patents. U.S. pharmaceutical companies argue that such decisions contribute to an uncertain business environment in Canada. For example, one U.S. pharmaceutical company challenged Canada under NAFTA’s Chapter 11 investor-state dispute settlement mechanism, based on a Canadian court’s decision to invalidate the company’s patent (see text box).

(...continued)

or domestically-supplied services.

75 USTR, 2013 Special 301 Report.

The Eli Lilly-Canada Chapter 11 Case

USTR has criticized the interpretation of utility in judicial invalidation of pharmaceutical patents, which has led to a NAFTA Chapter 11 investor-state dispute settlement case. The U.S. pharmaceutical company Eli Lilly has filed a Notice of Arbitration against the Government of Canada seeking damages in the amount of $500 million in lost sales stemming from the invalidation of patents for two medicines. In Canada, the patents for 18 drugs have been invalidated since 2002 through the use of the so-called promise doctrine, with an estimated loss of revenue to brand-name pharmaceutical companies of $1.1 billion. This common law doctrine, first invoked by the Supreme Court of Canada in 2002, states that the utility of a patent must be demonstrated or soundly predicted in the patent application. Lilly claims that this standard is discriminatory, contrary to utility standards in other countries and in NAFTA itself, and is adverse to Canada's own interpretation of utility at the time of NAFTA signing. This standard, some argue, makes it easier for generic companies to challenge the usefulness of a patented drug. The Government of Canada is currently assessing the information provided in the Notice of Arbitration filed by Eli Lilly on September 12, 2013, and vows to vigorously defend itself against the claims. However, some observers have maintained that there is no uniform standard for utility among countries, and no one standard enshrined in NAFTA.

U.S. Trade Law

Special 301

- Section 301 of the Trade Act of 1974 (P.L. 93-618), as amended, is the principal U.S. statute for identifying foreign trade barriers due to inadequate intellectual property protection. The 1988 Omnibus Trade and Competitiveness Act (P.L. 100-418) strengthened section 301 by creating “Special 301” provisions, which require the USTR to conduct an annual review of foreign countries' intellectual property policies and practices. By April 30th of each year, the USTR must identify countries that do not offer “adequate and effective” protection of IPR or “fair and equitable market access to United States person that rely upon intellectual property rights.” According to an amendment to the Special 301 provisions by the Uruguay Round Agreements Act (P.L. 103-465), the USTR can identify a country as denying sufficient intellectual property protection even if the country is complying with its TRIPS commitments. These findings are submitted in the USTR’s annual “Special 301” report.

- The USTR can designate countries in one of several statutorily- or administratively-created categories:

  - **Priority Foreign Country**: A statutory category for those designated by the USTR as having “the most onerous or egregious acts, policies or practices that deny intellectual property protection and limit market access to U.S. persons or firms depending on intellectual property rights protection” and the “greatest adverse impact (actual or potential) on the relevant United States products.”

---

77 Under NAFTA, patents shall be granted “provided that such inventions are new, result from an inventive step, and are capable of industrial application.” NAFTA provides that “inventive step,” and “capable of industrial application,” are synonymous with “non-obvious,” and “useful,” which underpins the concept of utility. Article 1709(1).

78 “Canada’s Internationally Inconsistent “Promise Doctrine” for Patents,” Eli Lilly background document.

79 “Canada: Eli Lilly Files Notice of Arbitration in $500 million NAFTA Dispute Against Canada,” Bereskin and Parr, LLP, September 24, 2013.

These countries may be investigated under section 301 provisions of the Trade Act of 1974. The USTR cannot identify countries as Priority Foreign Countries if they have entered into good faith negotiations or have made significant progress in improving their intellectual property protection record. If a country is named as a “Priority Foreign Country,” the USTR must launch an investigation into that country’s IPR practices. The USTR may suspend trade concessions and impose import restrictions or duties, or enter into a binding agreement with the priority country that would eliminate the act, policy, or practice that is the subject of the action to be taken. Since the WTO and its recourse to dispute settlement, the use of the first option may lead to the initiation of dispute settlement proceedings at the WTO for member countries, rather than unilateral retaliation. For the limited number of countries outside the WTO, trade sanctions remain a possibility.

- **Priority Watch List**: An administrative category created by the USTR for those countries whose acts, policies, and practices warrant concern, but who do not meet all of the criteria for identification as Priority Foreign Country. The USTR may place a country on the Priority Watch List when the country lacks proper intellectual property protection and has a market of significant U.S. interest.

- **Watch List**: An administrative category created by USTR to designate countries that have intellectual property protection inadequacies that are less severe than those on the Priority Watch List, but still attract U.S. attention.

- **Section 306 Monitoring**: A tool used by USTR to monitor countries for compliance with bilateral intellectual property agreements used to resolve investigations under section 301.

- **Out-of-Cycle Review**: A tool used by USTR on countries to monitor their progress on intellectual property issues, and which may result in status changes for the following year’s Special 301 report.

For the 2013 Special 301 Report, the USTR reviewed the IPR policies and practices of 95 countries, and designated them in one of the categories discussed above (see Table 4).

The Special 301 statute provides the overall guideline for identifying countries for the various lists. However, placement on one of the lists is country-specific and takes into consideration a host of factors, including the level and scope of the country’s IPR infringement and their impact on the U.S. economy, the strength of the country’s IPR laws and enforcement of IPR laws, progress made by the country in improving IPR protection and enforcement in the past year, and the sincerity of the country’s commitment to multilateral and bilateral trade agreements. There is no “weighting criteria” for the factors or a formula to determine the placement of a country on the watch list. Furthermore, no particular threshold exists for determining when a country should be upgraded or downgraded on the list. In making determinations, the USTR gathers information based on its annual trade barriers reports, as well as consultations with a wide variety of sources, including industry groups, other private sector representative, Congress, and foreign governments.

---

81 For the Special 301 provisions, see 19 U.S.C. §2242; Trade Act of 1974, as amended, (P.L. 93-618), §182.
Table 4. USTR 2013 Special 301 Report: Country Designations

<table>
<thead>
<tr>
<th>Special 301 Category</th>
<th>2013 Special 301 Designation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Priority Foreign Country</td>
<td>• Ukraine—based on concerns of the country's continued deterioration in IPR protection, enforcement, and market access for persons relying on IPR; the first time in seven years that the USTR has listed a country. In May 2013, USTR announced that the United States has initiated an investigation under section 301 of the Trade Act of 1974 of the IPR acts, policies, and practices of Ukraine. However, in March 2014, the USTR announced that it would not take any action against Ukraine in light of its political situation.</td>
</tr>
<tr>
<td>Priority Watch List</td>
<td>10 countries: Algeria, Argentina, Chile, China, India, Indonesia, Pakistan, Russia, Thailand, and Venezuela</td>
</tr>
<tr>
<td>Watch List</td>
<td>30 countries: Barbados, Belarus, Bolivia, Brazil, Bulgaria, Canada, Colombia, Costa Rica, Dominican Republic, Ecuador, Egypt, Finland, Greece, Guatemala, Israel, Italy, Jamaica, Kuwait, Lebanon, Mexico, Paraguay, Peru, Philippines, Romania, Tajikistan, Trinidad and Tobago, Turkey, Turkmenistan, Uzbekistan, and Vietnam</td>
</tr>
<tr>
<td>Section 306 Monitoring</td>
<td>China and Paraguay</td>
</tr>
<tr>
<td>Out-of-Cycle Reviews</td>
<td>• Spain—focusing on steps to combat copyright piracy over the Internet</td>
</tr>
<tr>
<td></td>
<td>• El Salvador—focusing on implementation of new legislation on pharmaceuticals and enforcement efforts</td>
</tr>
<tr>
<td></td>
<td>• &quot;notorious markets&quot;—including online markets, that reportedly engage in piracy and counterfeiting</td>
</tr>
</tbody>
</table>


Notes: For the 2013 Special 301 Report, the USTR reviewed the IPR policies and practices of 95 countries, and designated them in one of several categories.

Section 337

Section 337 of the Tariff Act of 1930 (19 U.S.C. 1337), as amended, prohibits unfair methods of competition or other unfair acts in the importation of products into the United States. It also prohibits the importation of articles that infringe valid U.S. patents, copyrights, processes, trademarks, semiconductor products produced by infringing a protected mask work (e.g., integrated circuit designs), or protected design rights. While the statute has been utilized to counter imports of products judged to be produced by unfair competition, monopolistic, or anti-competitive practices, it has become increasingly used for its IPR enforcement functions in recent years. Under the statute, the import or sale of an infringing product is illegal only if a U.S. industry is producing an article covered by the relevant IPR or is in the process of being established. However, unlike other trade remedies such as antidumping or countervailing duty actions, no showing of injury due to the import is required.

The U.S. International Trade Commission (ITC) administers section 337 proceedings. USITC must investigate complaints either brought to it or ones commenced under its own initiative. An administrative law judge provides an initial determination to the ITC which can accept the initial determination or order a further review of it in whole or in part. If the ITC finds a violation, it may issue two types of remedies: exclusion orders or cease and desist orders. The ITC may issue either a limited or general exclusion order enforced by U.S. Customs and Border Protection (CBP). A general exclusion order directs CBP to keep out all infringing articles regardless of the source. More commonly, a limited exclusion order is employed to exclude infringing articles.
from the firm subject to the ITC’s investigation. Alternatively, the ITC may enforce a cease and
desist order to stop the sale of the infringing product in the United States. However, the ITC may
consider several public interest criteria and decline to issue a remedy. Also, the President may
disapprove a remedial order during a 60 day review period for “policy reasons.” A presidential
review of a remedial order often considers several relevant factors, including “(1) public health
and welfare; (2) competitive conditions in the U.S. economy; (3) production of competitive
articles in the United States; (4) U.S. consumers; and (5) U.S. foreign relations, economic and
political.”

The number of Section 337 cases managed by the ITC has trended upward in recent years. The
overwhelming majority of Section 337 cases are patent-focused, involving high-technology
products, such as telecommunication and computer equipment (e.g., smartphones and tablets);
integrated circuits (e.g., memory chips); and display devices (e.g., digital televisions). Other
investigations concerned consumer items, and chemical and medical technologies. In addition, in
FY2012, the ITC saw an increase in the number of investigations involving alleged
misappropriation of trade secrets related to imported goods.

In the 112th Congress, legislative efforts related to Section 337 focused on addressing
jurisdictional problems associated with holding foreign websites accountable for piracy and
counterfeiting. Multiple bills were introduced, renewing congressional and public debate about
the balance between protecting U.S. intellectual property and promoting innovation. Congress
could take these issues up again, as well as other issues, including CBP’s enforcement of Section
337 exclusion orders.

**Generalized System of Preferences**

The Generalized System of Preferences (GSP) is a program that provides preferential duty-free
entry to certain products from designated developing countries. The purpose of the program is to
foster economic growth in developing countries by increasing their export markets. The Trade Act
of 1974 authorized the GSP for a ten-year time frame, and the program has been renewed from
time to time. The GSP program expired in 2013, and legislation considering its renewal could be
considered by Congress.

Although the GSP is non-reciprocal, it can be used to promote stronger intellectual property
protection and enforcement abroad. Under the GSP statute, the President must consider a set of
mandatory criteria that a country must fulfill in order to be designated as a GSP beneficiary.
Additionally, the President may evaluate a country on the basis of certain discretionary criteria,
including the country’s provision of IPR protection.

The GSP program undergoes an annual review by the GSP Subcommittee of the Trade Policy
Staff Committee (TPSC), which is headed by the USTR. As part of its evaluation, the TPSC
addresses concerns about specific country practices (such as intellectual property protection) and

---

83 ITC, FY2014 Congressional Budget Justification.
84 See CRS Report RL33663, Generalized System of Preferences: Background and Renewal Debate, by Vivian C.
   Jones.
makes recommendations to the President. Following the 2012 GSP Annual Review, the USTR has decided to continue to review IPR practices in Indonesia, Russia, Ukraine, and Uzbekistan, on the basis of IIPA petitions for ongoing GSP reviews.86

Issues for Congress

Congress has legislative, oversight, and appropriations responsibilities related to IPR and trade policy. What follows are certain key issues that Congress could consider as it fulfills those responsibilities.

U.S. Efforts to Promote IPR Through Trade Policy

Since the inclusion of IPR provisions in NAFTA and the TRIPS Agreement, IPR protection and enforcement have been major U.S. trade policy negotiating objectives. Alongside the growing role of IPR in trade policy, there has been an ongoing debate regarding the appropriateness of this role. From one perspective, IPR could promote trade through innovation, economic growth, and technology transfer from advanced to developing countries. From another perspective, IPR, which grant legal temporary monopolies to rights holders for their creations, could be considered barriers to trade with no place in trade liberalization negotiations. Given the continued use of trade policy to advance IPR objectives, debates also have focused on the appropriate balance between the protection and enforcement of IPR and other public policy objectives, such as access to medicines and the free flow of information, as well as the extent to which these goals are complementary or conflicting. Additionally, there have been debates about the trade policy channels used by the United States to promote IPR goals. Some question the appropriateness of using regional and bilateral FTAs for pursuing stronger IPR, contending that such actions take away from the effectiveness of multilateral IPR promotion efforts. Others argue that strong IPR commitments in U.S. regional and bilateral FTAs can provide momentum for developing such disciplines at the multilateral level.

U.S. IPR negotiating objectives may be affected by the language of any future TPA. In discussions about renewal of TPA, Congress may choose to consider possible reiteration or expansion on its IPR goals related to global health from the 2002 TPA. Congress also may choose to consider whether or not to follow the template provided by the Peru, Panama, and Colombia FTAs in future trade negotiations, such as negotiations on the Trans-Pacific Partnership Agreement. In addition, through the debate over TPA negotiating objectives, Congress is expressing concerns over new and emerging issues in IPR, such as those related to indigenous innovation, “forced” localization barriers to trade in the digital environment, and cybercrime.

Addressing IPR Trade Challenges in Emerging Economies

Some policymakers have voiced concern over the effectiveness of the current U.S. trade policy agenda in addressing IPR trade challenges associated with emerging economies, such as China, India, and Brazil—countries with which there are no existing U.S. FTAs and with which the United States is currently not negotiating any FTAs. Congress could examine how existing trade

policy tools are operating with respect to emerging economies. Beyond this, Congress could explore other options for advancing U.S. IPR trade policy objectives in emerging economies, including in the following areas:

- **U.S. FTA negotiations.** The TPP and TTIP negotiations are intended to help shape global rules addressing challenges in third countries, such as with respect to localization barriers to trade—issues relevant to emerging economies. Moreover, TPP negotiators seek to craft the TPP as an “open” and “living” agreement that other countries, such as China and India, could ultimately join if they were willing to take on its high standard commitments. Congress could consider to what extent the United States can or should encourage these emerging economies to join the TPP negotiations, and if so, how that might be accomplished.

- **Bilateral Investment Treaties (BITs).** Through the negotiation of BITs, the United States seeks to reduce barriers to foreign investment and strengthen protections for foreign investment.87 The U.S. Model BIT, the template the United States uses to negotiate BITs and investment chapters of FTAs, treats IPR as a covered form of investment subject to protections. Currently, the United States is negotiating BITs with both China and India. Congress could examine the progress of these negotiations, including how IPR issues are being addressed. Should these BIT negotiations be concluded, they would be subject to Senate ratification in order to enter into force.

- **U.S. trade promotion and preference programs.** Some stakeholders point to U.S. trade promotion and preference programs as a potential tool for Congress to encourage policy reform in emerging economies. For example, in light of heightened concern over India’s intellectual property environment, some stakeholders have called on Congress to remove India from the Generalized System of Preferences beneficiary list.88 Should Congress take up GSP reauthorization, India’s eligibility status could be among the issues examined.

- **WTO TRIPS Agreement.** Congress may examine how the WTO TRIPS Agreement is working with respect to emerging economies, as well as whether there are additional opportunities for seeking redress for violations of TRIPS Agreement commitments through the WTO Dispute Settlement Mechanism with these trading partners. For instance, the United States has seen some success in challenging China’s copyright practices through the WTO. Some stakeholders also call for the United States to pursue greater trade enforcement action on IPR with respect to other countries.

---

87 See CRS Report R43052, *U.S. International Investment Agreements: Issues for Congress*, by Shayerah Ilias Akhtar and Martin A. Weiss. U.S. BITs provide investment protections through provisions such as requirements for non-discriminatory treatment, protections against expropriation, and the right to neutral, binding arbitration to resolve disputes investors and host countries.

Effectiveness of the U.S. IPR Organizational Structure

The United States has a complex apparatus for supporting intellectual property rights, with responsibilities cutting across many different federal government agencies. For an overview of federal agencies and coordinating bodies involved in U.S. IPR-related efforts, see Appendix C. Some Members of Congress, private sector representatives, and other stakeholders express concern about whether the present U.S. IPR organizational structure is doing enough to enforce foreign countries’ IPR obligations, as well as whether the structure is capable of doing more.

One set of issues centers on coordination. Given the range of federal agencies involved in IPR protection and enforcement, questions have emerged about whether federal IPR activities are sufficiently coordinated in the present U.S. IPR organizational structure (see text box). On one hand, the Administration’s establishment of various interagency bodies related to IPR, such as the Intellectual Property Enforcement Coordinator (IPEC), National Intellectual Property Rights Coordination Center (NIPRCC), and Interagency Trade Enforcement Center (ITEC), affirms the U.S. commitment to enforcing IPR and the importance of interagency coordination. On the other hand, there are debates about whether the various IPR-related interagency coordinating mechanisms overlap. From one perspective, these interagency bodies focus on differing aspects of IPR protection and enforcement, and in doing so, collectively help to advance U.S. IPR goals in trade policy. From another perspective, the existence of multiple interagency coordinating bodies can contribute to additional bureaucracy.

Another set of issues centers on federal resources for IPR protection and enforcement. While protection and enforcement of IPR is a stated trade policy priority for the United States, it is difficult to get a sense of the magnitude of federal funding and resources devoted to it. Some U.S. government agencies do not have a separate budgetary line item for IPR-related activities, and Congress does not always designate specific funds for IPR activities in its appropriations for agencies. Additionally, there is limited information on the economic and other impacts of piracy and counterfeiting on the United States. This may complicate the ability of lawmakers to weigh the threat of IPR infringement against the federal resources available for IPR and other government priorities. Furthermore, there could be debates about whether attempts to enhance interagency coordination, without devoting greater resources to IPR enforcement activities, may translate into greater U.S. IPR enforcement.
Looking Forward

U.S. efforts to protect and enforce IPR through U.S. trade policy are likely to continue to be of interest for Congress. The reliance on IPR as a competitive advantage to drive an innovative U.S. economy is reflected in U.S. trade policy. Congress may set the course of U.S. trade policy concerning IPR through the development of negotiating objectives in any future trade promotion authority. It also may consider the treatment of IPR in ongoing U.S. negotiations of the Trans-Pacific and Trans-Atlantic FTAs. It may weigh the balance between greater intellectual property rights in free trade agreements and the ability to conclude agreements containing such provisions with other countries. It may wish to examine how to incorporate the IPR aspects of new issues such as digital trade in U.S. policy.

Congress may also wish to examine the enforcement of U.S. IPR through existing trade agreements. Congress may examine the effectiveness of such activities such as Special 301. Congressional debates may continue in areas such as how IPR protection and enforcement relate to other public policy goals, such as access to affordable medicines. Congress may also wish to examine the organizational structure for IPR protection and the priority to place on such enforcement when allocating budgetary resources.
## Appendix A. Summary of WIPO Treaties

<table>
<thead>
<tr>
<th>Treaty</th>
<th>Date Concluded</th>
<th>Provisions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Intellectual Property Protection Treaties</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paris Convention for the Protection of Industrial Property (Paris Convention)</td>
<td>1883 (entered into force 1884)</td>
<td>Protects industrial property (includes patents, marks, industrial designs, utility models, trade names, and geographic indications)</td>
</tr>
<tr>
<td>Berne Convention for the Protection of Literary and Artistic Works (Berne Convention)</td>
<td>1886 (entered into force 1886)</td>
<td>Protects literary and artistic works, providing right to control and receive payments for use of works</td>
</tr>
<tr>
<td>Madrid Agreement for the Repression of False and Deceptive Indications of Source on Goods (Madrid Agreement - Indications of Source)</td>
<td>1891</td>
<td>Requires States to seize imported goods with false/deceptive indications of source or to prohibit importation of such goods; open to States party to Paris Convention (1883)</td>
</tr>
<tr>
<td>Rome Convention for the Protection of Performers, Producers of Phonograms and Broadcasting Organizations (Rome Convention)</td>
<td>1961</td>
<td>Protects rights of performers against certain acts to which they have not agreed; protects rights of producers of phonograms, and broadcasting organizations to authorize/prohibit certain acts; open to States party to Berne Convention (1886)</td>
</tr>
<tr>
<td>Convention for the Protection of Producers of Phonograms Against Unauthorized Duplication of their Phonograms (Phonograms Convention)</td>
<td>1971</td>
<td>Protects producers of phonograms against unauthorized reproduction of their phonograms or importation of duplications for public distribution</td>
</tr>
<tr>
<td>Brussels Convention Relating to the Distribution of Programme-Carrying Signals Transmitted by Satellite (Brussels Convention)</td>
<td>1974</td>
<td>Protects against the unauthorized distribution of program-carrying signals transmitted by satellite</td>
</tr>
<tr>
<td>Nairobi Treaty on the Protection of the Olympic Symbol (Nairobi Treaty)</td>
<td>1981</td>
<td>Protects Olympic symbol against unauthorized commercial uses</td>
</tr>
<tr>
<td>Treaty on the International Registration of Audiovisual Works (Film Register Treaty)</td>
<td>1989</td>
<td>Establishes International Register for Audiovisual Works</td>
</tr>
<tr>
<td>Treaty on Intellectual Property in Respect to Integrated Circuits (Washington Treaty)</td>
<td>1989</td>
<td>Protects layout designs which display electrical components of an integrated circuit</td>
</tr>
<tr>
<td>Trademark Law Treaty (TLT)</td>
<td>1994</td>
<td>Streamlines national and regional trademark registration processes</td>
</tr>
<tr>
<td>WIPO Copyright Treaty (WCT)</td>
<td>1996 (entered into force 2002)</td>
<td>Special agreement under Berne Convention; grants exclusive rights to owners of copyright in computer programs and compilations of data/other material</td>
</tr>
<tr>
<td>WIPO Performances and Phonograms Treaty (WPPT)</td>
<td>1996 (entered into force 2002)</td>
<td>Grants exclusive rights to performers and phonogram producers</td>
</tr>
<tr>
<td>Patent Law Treaty (PLT)</td>
<td>2000 (entered into force 2005)</td>
<td>Aims to harmonize and streamline national and regional patent application procedures and patents</td>
</tr>
<tr>
<td>Singapore Treaty on the Law of the Trademarks</td>
<td>2006 (not yet in force)</td>
<td>Builds on TLT (1994); aims to harmonize trademark registration procedures; has wider scope (includes communication technology developments)</td>
</tr>
<tr>
<td>Beijing Treaty on Audiovisual Performances (Beijing Treaty)</td>
<td>2012 (not yet in force)</td>
<td>Seeks to strengthen economic rights of film actors and other performers through</td>
</tr>
<tr>
<td>Treaty</td>
<td>Date Concluded</td>
<td>Provisions</td>
</tr>
<tr>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>------------------------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Marrakesh Treaty to Facilitate Access to Published Works for Persons who are Blind, Visually Impaired or Otherwise Print Disabled (Marrakesh Treaty)</td>
<td>2013</td>
<td>Treaty to improve access to copyrighted works for the visually impaired and people with print disabilities</td>
</tr>
<tr>
<td><strong>Global Protection System Treaties</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure (Budapest Treaty)</td>
<td>1977 (entered into force 1980)</td>
<td>Special agreement under Paris Convention (1883); requires States to recognize the deposit of a microorganism with any “international depositary authority”</td>
</tr>
<tr>
<td>Madrid Agreement Concerning the International Registration of Marks (Madrid Agreement - Marks)</td>
<td>1891</td>
<td>Requires seizure of imported goods with false/deceptive indication of source or prohibition of importation of such goods; open to States party to Paris Convention (1883)</td>
</tr>
<tr>
<td>Hague Agreement Concerning the International Registration of Industrial Designs (Hague Agreement)</td>
<td>1925 (entered into force 1928)</td>
<td>Allows protection of industrial designs in all member states on basis of single application with WIPO; three acts currently in force: 1934, 1960, and 1999 Acts</td>
</tr>
<tr>
<td>Lisbon Agreement for the Protection of Appellations of Origin and their International Registration (Lisbon Agreement)</td>
<td>1958</td>
<td>Provides international protection for geographical indications</td>
</tr>
<tr>
<td>Patent Cooperation Treaty (PCT)</td>
<td>1970 (entered into force 1978)</td>
<td>Establishes an international patent filing system; allows a single international patent application to have legal standing in all countries signatory to PCT; open to States party to Paris Convention (1883)</td>
</tr>
<tr>
<td>Protocol Relating to the Madrid Agreement (Madrid Protocol )</td>
<td>1989 (entered into force 1995)</td>
<td>Relates to Madrid Agreement (1891); seeks to make Madrid system more amenable to domestic laws of certain who are not yet signatories to Madrid Agreement; open to States party to Paris Convention (1883)</td>
</tr>
<tr>
<td><strong>Classification Treaties</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nice Agreement Concerning the International Classification of Goods and Services of the Purposes of the Registration of Marks (Nice Agreement)</td>
<td>1957 (entered into force 1961)</td>
<td>Establishes a classification of goods and services in order to register trademarks and service marks; open to States party to Paris Convention (1883)</td>
</tr>
<tr>
<td>Locarno Agreement Establishing an International Classification for Industrial Designs</td>
<td>1968 (entered into force 1971)</td>
<td>Establishes a classification for industrial designs; open to States party to Paris Convention (1883)</td>
</tr>
<tr>
<td>Strasbourg Agreement Concerning the Industrial Patent Classification (Strasbourg Agreement)</td>
<td>1971 (entered into force 1975)</td>
<td>Establishes the International Patent Classification (IPC); open to States party to Paris Convention (1883)</td>
</tr>
<tr>
<td>Vienna Agreement Establishing Classification of the Figurative Elements of Marks (Vienna Agreement)</td>
<td>1973 (entered into force 1985)</td>
<td>Establishes a classification for marks which consist/contain figurative components; open to States party to Paris Convention (1883)</td>
</tr>
</tbody>
</table>

**Source:** WIPO.
## Appendix B. Patent and Copyright Provisions in the TRIPS Agreement and U.S. FTAs

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Patents</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patent term extensions</td>
<td>No provisions</td>
<td>Mandatory extensions in cases of unreasonable delays in patent grants/regulatory approval</td>
<td>Optional extensions in cases of unreasonable delays in patent grants/regulatory approval</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Jordan (Article 4.23.a), Chile (Article 17.9.6; 17.9.2a), Singapore (Article 16.7.7; 18.8.4a), Australia (Article 17.9.8; 17.10.4), Morocco (Article 15.9.7; 15.10.3), CAFTA-DR (Article 15.9.6; 15.10.2), Bahrain (Article 14.8.6), Oman (Article 15.8.6), Korea (Article 18.8.6)</td>
<td>NAFTA (Article 1709.12), Peru (Article 16.9.6), Panama (Article 16.9.6), Colombia (Article 16.9.6)</td>
</tr>
<tr>
<td>Market approval linked to patent status</td>
<td>No provisions</td>
<td>National regulatory authorities cannot provide marketing approval for a generic version of a patented drug without permission from rights-holder; also requires notification of rights-holder if marketing permitted</td>
<td>Eliminates mandate that regulatory authorities cannot approve a generic drug for marketing if patent for drug in place</td>
</tr>
<tr>
<td></td>
<td>NAFTA (no mention), Jordan (no linkage, but patent owner must be notified if another entity is seeking marketing approval for generic version of patented product, Article 4.23.b)</td>
<td>Chile (Article 17.10.2b), Singapore (16.8.4c), Australia (Article 17.10.4), Morocco (Article 15.10.4), CAFTA-DR (Article 15.10.2), Bahrain (Article 14.9.4), Oman (15.9.4), Korea (Article 18.9.5)</td>
<td>Peru (Article 16.10.4), Panama (Article 15.10.4), Colombia (Article 16.10.4)</td>
</tr>
<tr>
<td>Protection for undisclosed test or other data</td>
<td>Members must protect data from unfair commercial use (Article 39.3)</td>
<td>Provides for at least five years of data exclusivity from date of approval in country for pharmaceuticals that contain new chemical products</td>
<td>Provides for at least five years of marketing exclusivity from date of approval in country of first filing if new drug is granted marketing approval within six months in country of second filing</td>
</tr>
<tr>
<td></td>
<td>Jordan (Article 4.22)</td>
<td>NAFTA (Article 1711.6), Bahrain (Article 14.9.1), Oman (Article 15.9(1-2), CAFTA-DR (Article 15.10.1), Singapore (Article 16.8(1-3)), Australia (Article 17.10.1), Morocco (Article 15.10.1), Chile (Article 17.10.1), Korea (Article 18.9(1-2))</td>
<td>Peru (Article 16.10.2), Panama (Article 15.10.4), Colombia (Article 16.10.2)</td>
</tr>
<tr>
<td>Issuance of compulsory licenses</td>
<td>Some restrictions in issuance of compulsory licenses; circumstances under which licenses can be issued not limited (Article 13)</td>
<td>Limits issuance of compulsory license to specific cases: Correcting anti-competitive practices, public non-commercial contexts, national emergencies, and other</td>
<td>Not discussed</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chile (no mention), Morocco (no mention), CAFTA-DR (no mention), Bahrain (no mention), Oman (no mention)</td>
<td></td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-------------------------</td>
<td>---------------------------------------</td>
<td>-----------------------------------</td>
</tr>
<tr>
<td><strong>Intellectual Property Forms</strong></td>
<td><strong>TRIPS Provisions (1994)</strong></td>
<td><strong>General TRIPS-Plus Provisions in FTAs</strong></td>
<td><strong>Scale-down of TRIPS-Plus Standards</strong></td>
</tr>
<tr>
<td><strong>Parallel importing of patented products</strong></td>
<td>NAFTA (Article 1709.10), TRIPS will not be used to discuss IPR exhaustion (Article 6)</td>
<td>Extremely urgent situations</td>
<td>Peru (no mention), Panama (no mention), Colombia (no mention), (no mention)</td>
</tr>
<tr>
<td></td>
<td>Jordan (no mention), Chile (no mention), CAFTA-DR (no mention), Bahrain (no mention), Oman (no mention)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Biodiversity and traditional knowledge</strong></td>
<td>Members may exclude plants and animals from patentability (microorganisms and non-biological and micro-biological processes must be eligible for patents); must provide protection of plant varieties (Article 27.3(b))</td>
<td>Countries shall make patents available for plants and animals</td>
<td>Members may exclude plants and animals from patentability, but shall take reasonable effort to provide patent protection for plants or animals and maintain protection once offered</td>
</tr>
<tr>
<td></td>
<td>NAFTA (Article 1709.3), Bahrain (Article 14.8.1-2), Oman (Article 15.8.2, plants not discussed), Jordan, (no mention), Singapore (no mention), Australia (no mention), Korea (no mention)</td>
<td>Morocco (Article 15.9.2, plants and animals mentioned, plant varieties are not mentioned)</td>
<td>Chile (Article 17.9.2, mentions plants but not animals), CAFTA-DR (Article 15.9.2), Peru (Article 16.9.2), Panama (Article 15.9.2), Colombia (Article 16.9.2)</td>
</tr>
<tr>
<td><strong>Copyrights</strong></td>
<td>Rights-management information</td>
<td>Not discussed</td>
<td>Outlaws removal or alternation of information</td>
</tr>
<tr>
<td></td>
<td>NAFTA (no mention), Jordan (no mention)</td>
<td></td>
<td>Chile (Article 17.5.6), Australia (Article 17.4.8), Singapore (Article 16.4.8), Morocco (Article 15.5.9), CAFTA-DR (Article 15.5.8), Bahrain (Article 14.4.8), Oman (Article 15.4.8), Peru (Article 16.7.5), Panama (Article 15.5.8), Colombia (Article 16.7.5), Korea (Article 18.4.8)</td>
</tr>
<tr>
<td><strong>Term of protection</strong></td>
<td>No less than 50 years from authorized publication (Article 12)</td>
<td>No less than 70 years from death of author or authorized publication</td>
<td>Chile (Article 17.5.4), Singapore (Article 16.4.4), Australia (Article 17.4.4), Morocco (Article 15.5.5), CAFTA-DR (Article 15.5.4), Bahrain (Article 14.4.4), Oman (Article 15.4.4), Peru (Article 16.5.5), Panama (Article 15.5.4), Colombia (Article 16.5.5), Korea (Article 18.4.4)</td>
</tr>
<tr>
<td></td>
<td>NAFTA (Article 1705.4), Jordan (no mention)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Circumvention of copyrighted work</strong></td>
<td>Not discussed</td>
<td>Signatories must agree to prohibit circumvention</td>
<td>Jordan (Article 4.6), Chile (Article 17.5.5), Singapore (Article 16.4.7), Australia (Article 17.4.7), Morocco (Article 15.5.7), CAFTA-DR (Article 15.5.7), Bahrain (Article 14.4.7), Oman (Article 15.4.7), Peru (Article 16.7.4), Panama (Article 15.5.7), Colombia (Article 16.7.4), Korea (Article 18.4.7)</td>
</tr>
<tr>
<td><strong>ISP Liability</strong></td>
<td>Not discussed</td>
<td>ISPs are provided with limited liability in certain situations of copyright infringement on their servers if they comply with</td>
<td></td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-------------------------</td>
<td>--------------------------------------</td>
<td>-----------------------------------</td>
</tr>
<tr>
<td>(no mention)</td>
<td>regulations</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chile (Article 17.11.23), Singapore (Article 16.9.22), Australia (Article 17.11.29), Morocco, CAFTA-DR (Article 15.11.27), Bahrain, Oman (Article 15.10.29), Peru (Article 16.11.29), Panama (Article 15.11.27), Colombia (Article 16.11.29), Korea (Article 18.10.30)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Source:** CRS Analysis of FTA provisions.

**Note:** When there is no mention of an issue in an FTA, the TRIPS standard generally holds.
Appendix C. Overview of IPR-Related U.S. Government Agencies and Coordinating Bodies

What follows is a discussion of key U.S. government agencies and coordinating bodies involved in U.S. efforts to protect and enforce IPR.

Office of the United States Trade Representative (USTR)

The USTR is the lead U.S. trade negotiator and negotiates IPR provisions in U.S. trade agreements, at the multilateral, plurilateral, regional, and bilateral levels. Currently, the USTR is negotiating the proposed TPP and TTIP agreements.89 It also enforces U.S. rights under existing trade agreements. Additionally, through its annual Special 301 Report, USTR is charged with monitoring the adequacy and effectiveness of IPR protection of our trading partners as well as their compliance with bilateral and multilateral trade agreements, to identify countries not in compliance with such agreements, and to negotiate with those countries better compliance. The USTR further administers the GSP program, under which a country’s eligibility for U.S. trade preferences may be contingent on its IPR protection.

Department of Commerce (Commerce)

Two agencies within the Department of Commerce, the Patent and Trademark Office and the International Trade Administration, address IPR issues.90

- The Patent and Trademark Office (PTO) administers the U.S. laws pertaining to patents and trademarks. It processes patent and trademark applications, and issues patents and registers trademarks. The PTO develops IPR protection and enforcement policy and collaborates with other agencies to develop intellectual property provisions in FTAs and other international agreements. Additionally, the PTO offers training, technical assistance, and trade capacity building programs to assist in promoting strong IPR regimes in foreign countries.91 Its IPR Attaché Program places individuals with technical expertise and experience overseas to promote strong international IPR protection and enforcement, such as through helping to influence laws, regulations, and practices in host countries. The PTO does not have jurisdiction over determining patent and trademark infringements; such determinations and remedies are made at the U.S. federal district court level or through the U.S. International Trade Commission’s section 337 proceedings (discussed above). The PTO is fully funded through fees generated from patent and trademark applications.

90 General information about the Department of Commerce is available at http://www.doc.gov.
The **International Trade Administration (ITA)** administers many of the international trade programs of the Department of Commerce, include aspects involving IPR. The ITA monitors foreign countries’ progress in implementing intellectual property agreements; reviews Generalized System of Preferences (GSP) petitions submitted by industry and coordinates the Commerce Department’s response to these petitions; represents the Commerce Department at the WTO TRIPS Council; meets with trading partners to advance U.S. intellectual property interests abroad; and works with U.S. businesses and industry groups to make sure that IPR-related trade concerns are addressed.92

**Department of Justice (DOJ)**

The DOJ enforces criminal laws that protect IPR in the United States and internationally through the prosecution of intellectual property cases. Key units of the DOJ that have IPR enforcement responsibilities are the Criminal Division, U.S. Attorney’s Office, the Civil Division, the Federal Bureau of Investigation, and the Office of Justice Programs.

- The **Criminal Division** prosecutes intellectual property crimes involving criminal offenses, namely through its Computer Crime and Intellectual Property Section (CCIPS).
- Federal prosecutors in the **U.S. Attorneys’ Offices** pursue computer crime and intellectual property offenses.
- The **Federal Bureau of Investigation (FBI)** has an intellectual property enforcement program focusing on intellectual property crimes that have the most bearing on national and economic security, such as trade secret theft, Internet priority, and counterfeit tracking goods. Its IPR mission is to “disrupt and dismantle state sponsored groups and international and domestic criminal organizations that steal, manufacture, distribute and otherwise profit from the theft of intellectual property.” IPR is a top priority of the cyber division, though IPR crimes may be investigated in other divisions. Other IPR priorities for investigations are counterfeit health and safety products and theft of trade secrets.
- The **Civil Division** prosecutes civil actions to recover penalties imposed by the Department of Homeland Security’s Customs and Border Protection (CBP, discussed below) with respect to importation of counterfeit goods, brings affirmative cases when U.S. intellectual property rights are infringed, and defends CBP enforcement of the International Trade Commission’s Section 337 exclusion orders, among other things.
- The **Office of Justice Program** awards grants to support intellectual property enforcement efforts by state and local law enforcement partners.

In addition to enforcement activities, the DOJ also works with Congress to develop laws that increase protection of IPR and provides training and technical assistance programs on IPR enforcement through its Criminal Division.

---

Department of Homeland Security (DHS)

One of the aims of DHS is to ensure the facilitation of legitimate trade, while enforcing U.S. trade and IPR laws and investigating IPR violations, specifically trademark, counterfeiting, and copyright piracy. Key parts of DHS that are involved in IPR enforcement include U.S. Customs and Border Protection, U.S. Immigration and Customs Enforcement, U.S. Secret Service (USSS), and the National Intellectual Property Rights Coordination Center.

- **Taking the lead in day-to-day IPR enforcement activities at the U.S. border, the Customs and Border Protection (CBP)** is responsible for detecting and seizing counterfeit and pirated goods entering the United States and determining penalties for infringement.\(^{93}\) CBP has the authority to determine whether or not imports infringe federally registered trademarks and copyrights and to detain or seize such infringing goods. Owners of copyrights and trademarks are able to record information about their rights in the CBP’s electronic IPR database. As noted earlier, in contrast to trademarks and copyrights, CBP does not have the jurisdiction to make determinations about patent infringements. However, it is able to block imports determined by the ITC to infringe a U.S. patent by a Section 337 investigation.\(^{94}\)

- **Immigration and Customs Enforcement (ICE)** is charged with investigating violations of U.S. law that are connected with U.S. borders. ICE identifies, investigates, apprehends, and removes international criminal groups and other criminals. ICE conducts inquiries into the importation and distribution of counterfeit goods. ICE activities are closely linked with those of CBP. For instance, when CBP identifies and seizes counterfeit goods, the issue is referred to ICE for criminal investigation. Likewise, information obtained from ICE that is relevant to identifying and apprehending counterfeit shipments is provided to CBP.

- **The U.S. Secret Service (USSS)** investigates violations of laws relating to counterfeiting of obligations and securities of the United States; financial crimes; and computer-based attacks on U.S. financial, banking, telecommunications, and other critical infrastructure. As part of such activities, USSS may find links to IPR violations.

Department of Health and Human Services

The FDA, which is an agency of the Department of Health and Human Services (DHHS), is responsible for protecting public health by ensuring the safety and effectiveness of medicines, food, and other products. As part of its activities, the FDA works to protect consumers against counterfeit medicines. To combat the entry of foreign counterfeit drugs into the U.S. drug supply, the FDA works in conjunction with the CBP to conduct border inspections of FDA-regulated products. The FDA also engages in foreign inspections to ensure that foreign manufacturers meet

\(^{93}\) Certain customs-related IPR policy-making resides within the Treasury.

FDA quality and labeling requirements. Funding for preventing counterfeits from entering the United States is part of overall FDA import safety efforts.95

Library of Congress

The Copyright Office of the Library of Congress administers U.S. copyright law by registering claims to copyright and related documents, including “assignments or transfers of rights” and maintains information on registrations, recordings, compulsory licenses, and other copyright-related actions. Additionally, the Copyright Office provides legal and technical expertise on national and international copyright issues to the U.S. government. The Copyright Office also works with other federal agencies to provide assistance and advice in negotiations for international intellectual property agreements, as well as technical assistance to foreign countries crafting their own copyright laws.96

Department of State

The Department of State represents U.S. views in both bilateral and multilateral arenas. It works to build international consensus for IPR enforcement. Information from State’s foreign postings informs the USTR Special 301 review. In particular, the Bureau of International Narcotics Control and Law Enforcement (INCLE) works to combat intellectual property piracy, while the Bureau of Economics and Business Affairs supports stronger international IPR standards to combat global piracy and counterfeiting.97

U.S. Agency for International Development (AID)

AID funds training and technical assistance to improve the compliance with the TRIPS Agreement and bilateral trade agreements with the United States. Funding for these projects generally have been undertaken by regional or country missions; there is no separate budgetary line item for IPR enforcement and training.98

United States International Trade Commission (ITC)

The ITC is a quasi-judicial federal government agency responsible for investigating and arbitrating complaints of unfair trade practices. The ITC adjudicates allegations of imported products that infringe U.S. patents, trademarks, and copyrights through its section 337 proceedings (see above). The primary remedy employed by the ITC is to order the CBP to stop imports from entering the border. Additionally, the ITC may issue “cease and desist” orders against individuals determined to be IPR violators. Damages for IPR infringement cannot be

received through ITC court proceedings; right holders seeking damages must file a civil action with a U.S. federal district court.\textsuperscript{99}

Coordinating and Advisory Bodies

The USTR leads interagency coordination of U.S. trade policy formulation, negotiation, and implementation. Beyond this general mechanism, the U.S. government also has interagency intended to specifically coordinate IPR protection and enforcement activities, as well as private sector advisory bodies that provide input into the formulation of U.S trade policy. Certain key coordinating and advisory bodies are outlined below.

\textbf{Office of the U.S. Intellectual Property Enforcement Coordinator (IPEC)}

The IPEC, located in the Office of Management and Budget (OMB) of the Executive Office of the President, provides executive direction and coordination of federal agencies involved in IPR enforcement. The position of the U.S. Intellectual Property Enforcement Coordinator, subject to Senate confirmation, was statutorily established in October 2008, through the Prioritizing Resources and Organization for Intellectual Property Act of 2008 (P.L. 110-403).\textsuperscript{100} Among its key responsibilities are to develop and implement a “Joint Strategic Plan on Intellectual Property Enforcement” for combating counterfeiting and piracy (see \textbf{text box}); provide assistance to the USTR in conducting trade negotiations relating to IPR enforcement abroad; and chair an Advisory Committee composed of representatives from the OMB; Departments of Justice, Commerce, State, Homeland Security, Agriculture; FDA; AID; and the Register of Copyrights.

\textbf{National Intellectual Property Rights Coordination Center (NIPRCC)}

The Department of Homeland Security houses the NIPRCC, a task force for optimizing the roles and law enforcement of member agencies and enhancing government-industry partnerships to support IPR enforcement initiatives. NIPRCC is run jointly by ICE and the FBI. According to USTR, NIPRCC can be distinguished from ITEC because of the former’s focus on the law enforcement response to IPR theft (primarily coordinating investigation and prosecution of IPR infringers under U.S. criminal laws) and the latter’s focus on enforcement of U.S. rights under trade agreements across a range of issues, one of which is IPR.\textsuperscript{101}

\textbf{Interagency Trade Enforcement Center (ITEC)}

The ITEC is an interagency coordinating body established in February 28, 2012, by Executive Order. Its aim is to strengthen and coordinate enforcement of U.S. rights under international free


\textsuperscript{100} In creating the IPEC, P.L. 110-403 repealed the authorities creating the National Intellectual Property Law Enforcement Coordination Council (NIPLECC). Established by Congress in 1999, NIPLECC coordinated U.S. activities to protect and enforce IPR domestically and abroad, drawing together the major federal agencies the help to enforce IPR. The Copyright Office participated in the Council in an advisory role. The U.S. Coordinator for International Intellectual Property Enforcement headed NIPLECC’s interagency coordination efforts. NIPLECC, \textit{Report to the President and Congress on Coordination of Intellectual Property Enforcement and Protection}, January 2008, pp. 3-4.

\textsuperscript{101} USTR, “ITEC Frequently Asked Questions.”
trade agreements and of U.S. trade laws.\(^{102}\) The ITEC is housed within the USTR with a designated director from the USTR; a designated deputy director from the Department of Commerce; and support from the Departments of State, the Treasury, Justice, Agriculture, Commerce, and Homeland Security, as well as the Director of National Intelligence. The Administration has emphasized the need for creating the ITEC in order to better combat unfair trade practices by countries such as China. According to USTR, the creation of ITEC will double the resources to bring trade dispute resolution cases at the WTO “more effectively and more swiftly.”\(^{103}\)

**Private Sector Advisory Committee System**

The USTR manages a private sector advisory committee system for trade policy, intended to provide information and advisory on U.S. negotiating objectives and bargaining positions before the United States enters into trade agreements, the operation of existing U.S. trade agreements, and other U.S. trade policy matters.\(^{104}\) Statutorily established under section 135 of the Trade Act of 1974 (P.L. 93-618), the private sector advisory system includes 16 Industry Trade Advisory Committees (ITACs), which are jointly administered by the USTR and Department of Commerce. ITAC membership draws from industry and labor. The ITACs reflect a range of U.S. economic sectors and policy issues, and one of the ITACs focuses on IPR.\(^{105}\)

**Author Contact Information**

<table>
<thead>
<tr>
<th>Shayerah Ilias Akhtar</th>
<th>Ian F. Fergusson</th>
</tr>
</thead>
<tbody>
<tr>
<td>Specialist in International Trade and Finance</td>
<td>Specialist in International Trade and Finance</td>
</tr>
<tr>
<td><a href="mailto:siliasakhtar@crs.loc.gov">siliasakhtar@crs.loc.gov</a>, 7-9253</td>
<td><a href="mailto:ifergusson@crs.loc.gov">ifergusson@crs.loc.gov</a>, 7-4997</td>
</tr>
</tbody>
</table>


\(^{104}\) USTR, “Advisory Committees,” http://www.ustr.gov/about-us/intergovernmental-affairs/advisory-committee.s